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Neuromyelitis optica (NMO) is a demyelinating autoimmune disease of the central 
nervous system (CNS), with serum anti-aquaporin4 (AQP4) antibodies (Ab) detected in the 
majority of patients. Binding of NMO-Ab to AQP4 results in complement- and cell-mediated 
astrocyte depletion. In addition, a severe impairment of the blood-brain barrier (BBB) is 
observed as evidenced by gadolinium-enhanced lesions on magnetic resonance imaging 
(MRI). To investigate the structural, molecular and cellular correlates of the BBB breakdown, 
we employed a focal model of NMO-like lesions in rats which is based on the intracerebral 
injection of a human recombinant NMO-Ab directed against AQP4, and human complement. 
Astrocytes and pericytes are considered crucial for maintenance and repair of the BBB. In 
NMO-like lesions, we demonstrated that a transient breakdown of the BBB coincided with 
the onset of astrocyte loss. However, the BBB integrity to vascular tracers was rapidly 
restored, even in the absence of astrocytes. No loss of pericytes from NMO-like lesions was 
observed indicating that pericytes might contribute to the rapid restoration of the BBB. 
Tight junctions (TJ) restrict the paracellular diffusion of solutes across the BBB. Therefore, 
we analyzed the TJ in NMO-like lesions and detected a transient loss of the TJ protein 
occludin, while the expression of claudin-3 and claudin-5 was not altered. However, no 
morphological alterations of the TJ were observed on the ultrastructural level, and the 
integrity of the BBB to vascular tracers was re-established in the absence of occludin. 
Inflammatory cells infiltrating the CNS were shown to contribute to BBB disruption. In 
early NMO-like lesions we demonstrated that polymorphonuclear cells (PMN) were the most 
abundant infiltrating leukocytes and that the number of PMN in the lesions correlated with 
the extent of vascular tracer extravasation. Depletion of PMN prevented not only the 
breakdown of the BBB, but interestingly also the loss of astrocytes. Furthermore, we could 
show that inhibition of the complement component C5a receptor (C5aR), which is important 
for PMN attraction and activation, reduced the area of astrocyte loss in NMO-like lesions. In 
addition, proteases released from PMN granules upon activation were implied in BBB 
disruption. We demonstrated that matrix metalloproteinase 9 (MMP9) decreased the 
electrical resistance of endothelial monolayers and that inhibition of the neutrophil elastase 
(NE), another PMN protease, reduced the loss of astrocytes and PMN infiltration in vivo.  
This study affirms the importance of PMN in the development of NMO-like lesions and is 
the first to show that infiltrating PMN mediate the breakdown of the BBB. These findings, 
together with the detection of PMN in early human NMO lesions, identify the PMN mediated 
breakdown of the BBB as a promising target for future therapeutic approaches.  
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1.1 Neuromyelitis optica 
Neuromyelitis optica (NMO) is an idiopathic demyelinating disease of the central nervous 
system (CNS). It is also known as Devic’s disease, named after the French neurologist Eugène 
Devic. Devic and his student Gault established the syndrome with the characteristics of 
acute myelitis and optic neuritis in 1894 (Devic, 1894; Gault, 1894). Whether NMO 
represents a variant of multiple sclerosis (MS) was discussed for a long time since NMO and 
MS both share the features of inflammatory demyelination, optic neuritis and myelitis. 
However, today NMO is recognized as a separate disease entity with specific clinical and 
pathological features. The discovery of a specific NMO-antibody (Ab) in 2004 by Lennon and 
coworkers contributed substantially to the understanding of the pathogenesis of NMO 
(Lennon et al., 2004; Lennon, 2005). 
1.1.1 Clinical presentation and disease course 
Characteristic features of NMO are severe attacks of optic neuritis and longitudinally 
extensive transverse myelitis. Frequently, attacks of optic neuritis and myelitis occur 
sequentially with separating periods spanning sometimes years or decades (Wingerchuk et 
al., 1999). Patients typically present with loss of vision, severe symmetric paraplegia, sensory 
disturbances and loss of bladder control (Wingerchuk et al., 2007). Cervical spinal cord 
lesions may extend into the brain stem, resulting in symptoms like vomiting, nausea and 
intractable hiccups (Almekhlafi et al., 2011; Misu et al., 2005; Wingerchuk et al., 1999). 
Although brain lesions were historically viewed as an exclusion criterion for the diagnosis of 
NMO (Wingerchuk et al., 1999), brain abnormalities detected by magnetic resonance 
imaging (MRI) are described in about 50 - 65% of NMO patients which are normally clinically 
silent. About 10% of the patients develop unique NMO brain lesions in the hypothalamus, 
corpus callosum, brainstem or periventricular (Bichuetti et al., 2008; Cabrera-Gomez et al., 
2007; Pittock et al., 2006). The revised criteria for NMO include acute myelitis and optic 
neuritis as absolute criteria. Furthermore, 2 of the following 3 criteria are required: 
longitudinally extensive myelitis with lesions spanning typically 3 or more contiguous 
vertebral segments, negative or MS atypical brain MRI and NMO-IgG seropositivity 
(Wingerchuk et al., 2007). 
A relapsing-remitting (RR) disease course is the most common form in NMO which affects 80 




(Wingerchuk et al., 1999). The recovery after attacks is incomplete and results in the attack-
related development of permanent disabilities. Disabilities like blindness or paraplegia are 
often severe and accumulate rapidly (Wingerchuk et al., 1999; Wingerchuk et al., 2007). 
1.1.2 Epidemiology 
NMO more frequently affects females than males with a ratio of 9:1. The median age of 
onset is in the late thirties, however, NMO can also affect young children or older people 
(Asgari et al., 2011; Cabre et al., 2001; Cabrera-Gomez et al., 2009; Kuroiwa et al., 1975; 
Rivera et al., 2008). In one study, e.g., the reported age at disease onset ranged from 3-81 
years (Mealy et al., 2012). NMO is a rare disease, and population based studies suggest 
yearly incidence rates of 0.053 to 0.4 NMO cases per 100,000 persons and prevalence rates 
of 0.52 to 4.4 per 100,000 (Asgari et al., 2011; Cabre et al., 2001; Cabrera-Gomez et al., 
2009; Kuroiwa et al., 1975; Rivera et al., 2008). 
1.1.3 Pathogenesis 
NMO is a severe demyelinating autoimmune disease with the astrocyte as the main target. 
About 70% of the patients are seropositive for specific NMO-Ab directed against aquaporin4 
(AQP4), a water channel expressed on astrocytic endfeet (Jarius et al., 2011; Lennon et al., 
2005; Lennon et al., 2004; Mealy et al., 2012). Several observations in patients indicate a 
pathogenic role of NMO-Ab: complement and Ab depositions together with loss of AQP4 
immunoreactivity were observed in human NMO lesions (Hinson et al., 2007; Roemer et al., 
2007). Furthermore, NMO-Ab levels correlated with disease activity (Jarius et al., 2012a; Kim 
et al., 2012; Takahashi et al., 2007), and B-cell depletion and plasma exchange are beneficial 
for NMO patients (Bonnan et al., 2009; Cree et al., 2005; Watanabe et al., 2007). In addition, 
NMO-Ab were shown to be pathogenic in various in vitro and in vivo studies. NMO-Ab 
induced astrocyte death was demonstrated to be mediated by complement-dependent and 
cell-mediated cytotoxicity (CDC and ADCC) (Phuan et al., 2012; Ratelade et al., 2013; Vincent 
et al., 2008; Wrzos et al., 2014; Zhang and Verkman, 2013). Furthermore it was shown in vivo 
that passive transfer of NMO-Ab into rats with experimental autoimmune encephalomyelitis 
(EAE), an inflammatory disease commonly used as an experimental model for MS, results in 
NMO-like lesions in the recipient animals (Bennett et al., 2009; Bradl et al., 2009; Kinoshita 
et al., 2009; Wrzos et al., 2014). Similarly, development of NMO-like lesions was observed 
after intracerebral injection of NMO-Ab together with human complement in rats and mice 




lesions were characterized by loss of astrocytes and oligodendrocytes, demyelination, 
immune cell infiltration and deposits of complement and immunoglobulin (Ig) G. 
With regard to disease effector mechanisms, CDC and ADCC were found to be relevant in 
experimental models. Furthermore, also in human NMO therapeutic approaches indicate an 
important role of CDC in the disease process. Using a C1-esterase inhibitor (Cinryze®) as add-
on therapy to prevent the activation of the complement cascade after the binding of the 
NMO-Ab to AQP4 in NMO lesions reduced neurologic damage, and improved outcomes 
were observed in a phase 1 open-label trial (Levy and Mealy, 2014). Another open-label trial 
used the monoclonal antibody eculizumab that is directed against the complement 
component C5 and thereby inhibits the effector pathway of the complement cascade. 
Treatment of RR NMO patients with eculizumab significantly reduced attack frequency and 
improved or stabilized the neurological disability measures (Pittock et al., 2013). 
1.1.4 Histopathology of human NMO lesions 
NMO lesions in the CNS are characterized by extensive demyelination and astrocyte loss 
which may affect both the grey and white matter. Furthermore, demyelination is associated 
with a pronounced reduction in the numbers of oligodendrocytes (Lucchinetti et al., 2002; 
Parratt and Prineas, 2010; Wrzos et al., 2014). Early NMO lesions present with relative 
axonal preservation (Figure 1 B), while in more advanced stages of lesion development 
axonal loss is observed (Lucchinetti et al., 2002; Parratt and Prineas, 2010). Unique for NMO 
lesions is the extensive loss of astrocytes (Hinson et al., 2007; Roemer et al., 2007). 
Interestingly, loss of AQP4 immunoreactivity exceeds the loss of glial fibrillary acidic proteins 
(GFAP) immunoreactivity, an intermediate filament protein used as marker for astrocytes, 
within NMO lesions (Figure 1 C vs. D; Parratt and Prineas, 2010). Furthermore, perivascular 
IgG and IgM deposits associated with immunoreactivity for the terminal complement 
membrane attack complex are observed in a characteristic rim and rosette pattern in active 
NMO lesions (Lucchinetti et al., 2002). Moreover, focal deposits of Ig and complement 
coincide with areas of AQP4 loss (Hinson et al., 2007; Roemer et al., 2007). Vascular Ig and 
fibrinogen deposits (Figure 1 E) also indicate a loss of blood-brain barrier (BBB) integrity in 
NMO lesions. In addition, blood vessels are thickened and hyalinized (Lucchinetti et al., 
2002; Mandler et al., 1993). The immune cell infiltrate in NMO lesions consists of 
monocytes, abundant numbers of macrophages, lymphocytes and polymorphonuclear cells 





Figure 1: Early NMO lesions are characterized by loss of GFAP and AQP4 immunoreactivity, 
demyelination, relative axonal preservation and breakdown of the BBB 
Representative microphotographs of an early NMO lesion are depicted (autopsy tissue, patient 6). NMO lesions 
present with demyelination (A, myelin is stained in blue, dotted line indicates lesion border) with relative 
axonal preservation (B). Loss of astrocytes is apparent in GFAP (C, brown) and AQP4 (D, brown) 
immunohistochemistry with loss of AQP4 immunoreactivity exceeding the area of GFAP loss. Deposits of 
fibrinogen indicate loss of BBB integrity (E, brown). Asterisks indicate the same vessel in serial sections. Scale 
bar 200 µm, scale bar in inserts 50 µm 
1.1.5 The blood-brain barrier in NMO  
Although the NMO-Ab present in NMO patients was shown to be pathogenic in animal 
experiments, it is not known precisely which conditions result in its pathogenicity. In a case 
report one patient was described to have been seropositive for NMO-Ab more than 10 years 
before disease onset (Nishiyama et al., 2009). This is supported by observations in vivo 
where intravenous (i.v.) injection of NMO-Ab in rats did not result in lesion formation (Bradl 
et al., 2009) which indicates that an intact BBB prevents the passage of the NMO-Ab into the 
brain parenchyma. Attempts to deliver NMO-Ab to the CNS using juvenile rats in which the 
BBB was described to be leaky did also not result in lesion formation (Bradl et al., 2009). 
Similar results were obtained after mechanical brain injury in NMO-Ab seropositive mice 




impairment of the BBB may be required for the NMO-Ab to become fully pathogenic. Indeed 
it was demonstrated that the induction of non-specific inflammation and the disruption of 
the BBB by treatment with complete Freund’s adjuvant is sufficient to induce the 
development of NMO-like lesions in seropositive rats (Kinoshita et al., 2010). 
The BBB in NMO patients is severely impaired which is evidenced by the presence of 
multiple gadolinium enhancing lesions in the CNS on MRI (de Seze et al., 2002; Ito et al., 
2009; Kim et al., 2015; Wingerchuk et al., 1999). The disruption of the BBB is associated with 
edema and infiltration of inflammatory cells. Furthermore, it was demonstrated that the 
disease severity correlates with the extent of BBB permeability. Investigating the ratio of 
cerebrospinal fluid (CSF):serum albumin as a measure for BBB permeability Tomizawa and 
coworkers demonstrated that the breakdown of the BBB in NMO is more severe than in MS 
and correlates with expanded disability status scale (EDSS) scores during the acute phase of 
the disease (Tomizawa et al., 2012). 
Furthermore it was shown in vitro that incubation of brain endothelial cells (EC) with serum 
isolated from NMO-patients during the acute phase of the disease increases the 
transendothelial permeability and decreases the expression of the tight junction (TJ) protein 
claudin-5. This was significant compared to serum from MS patients or healthy controls 
(Shimizu et al., 2012; Tasaki et al., 2014). Furthermore, upregulation of cytokines 
(Chemokine (C-X-C motif) ligand (CXCL)10, Chemokine (C-C motif) ligand (CCL)2, CCL5, 
interleukin (IL)-6), the adhesion molecule VCAM-1, the matrix metalloproteinases (MMPs) -2 
and -9 and vascular endothelial growth factor (VEGF) by brain EC were observed after 
treatment with NMO patient serum (Shimizu et al., 2015; Shimizu et al., 2012; Tasaki et al., 
2014). However, how serum from NMO patients mediates these effects is so far not known. 
The authors proposed that humoral factors present in the blood during acute NMO disease 
phases might play a role, including autoantibodies directed against EC. In vitro work of a 
second group investigated the effect of the NMO-Ab on the permeability of endothelial 
monolayers in a co-culture model of the BBB consisting of astrocytes and EC. They 
demonstrated that astrocytes express AQP4 in a polarized pattern, concentrated on the 
astrocytic endfeet. Binding of NMO-Ab to AQP4 leads to a depolarized expression and 
internalization of AQP4 which in turn results in an increase in the permeability of the 
endothelial/astrocyte barrier (Vincent et al., 2008). In conclusion, the integrity of the BBB in 




during the acute phase of the disease. However, how the permeability of the BBB is 
regulated during the disease course is not known. 
1.2 The BBB 
The phenomenon of the BBB was first noted by Paul Ehrlich. He observed that after 
peritoneal injection of hydrophilic dyes all peripheral organs were stained but not the CNS. 
He presumed that this difference in staining intensity was due to the different binding 
affinities of various tissues to different dyes (Ehrlich, 1885). The concept of the BBB as a 
highly selective permeability barrier was developed only later with the conclusion that 
“brain capillaries must hold back certain molecules” (Goldmann, 1913; Lewandowski, 1900). 
Subsequently, this observation was associated with the molecular correlates at the level of 
EC, the TJ which seal the intercellular gap between adjacent EC and prevent paracellular 
leakage of solutes (Reese and Karnovsky, 1967). In addition, the BBB controls movements of 
nutrients, electrolytes, neuroactive agents and neurotransmitters as well as potential 
neurotoxins from the blood into the brain, and furthermore mediates the efflux of waste 
products. Thereby the BBB forms a physical, metabolical and transport barrier that is crucial 
for the maintenance of the unique CNS environment which enables neuronal function 
(Abbott et al., 2010; Abbott et al., 2006; Wolburg et al., 2008). 
1.2.1 The BBB phenotype of brain endothelial cells 
Brain EC express a variety of transporters and specialized enzyme systems which results in 
the selective uptake of polar molecules from the blood into the brain. Solute carriers 
transport polar molecules and supply the brain with nutrients such as glucose (e.g. via 
glucose transporter 1), amino acids (e.g. via the L-system for large neutral amino acids or the 
glycine transporter), nucleosides, nucleotides, nucleobases (e.g. via the equilibrative 
nucleoside transporter 1), and organic ions (e.g. organic cation transporters) (Boado et al., 
1999; Borowsky et al., 1993; Gorboulev et al., 1997; Griffiths et al., 1997; Mueckler et al., 
1985). Solute carriers not only facilitate the transport of molecules into the brain, but also 
the transport of waste products back from the brain into the blood. Beside solute carriers, 
ATP-binding cassette (ABC) transporters play an important role for the BBB phenotype. They 
restrict the entry of lipophilic molecules into the brain and function as active efflux pumps to 
remove potentially neurotoxic compounds from the CNS. At the BBB, e.g. P-glycoproteins, 
multidrug resistance-associated proteins and breast cancer resistance proteins are 




al., 2000). A third transport pathway is the transcytosis of macromolecules which can be 
either receptor- or adsorption mediated (Drin et al., 2003; Pan et al., 2000; Pardridge et al., 
1990; Visser et al., 2004; Zlokovic et al., 1990). However, endocytotic vesicles in brain EC are 
less frequent than in the endothelium of other organs although they might increase during 
BBB inflammation (Claudio et al., 1989). 
The selectivity of the transport into the brain is maintained by the formation of a physical 
barrier restricting the paracellular diffusion of molecules. Brain EC develop tight 
interendothelial junctions, i.e. the TJ, which restrict the paracellular movement of even ions 
like Na+ and Cl-. The transendothelial resistance (TEER) is a measure of this ion flux 
restriction and reaches values of about 1800 Ω*cm² in the brain endothelium of adult rats 
while values in peripheral capillaries range only from 2-20 Ω*cm² (Butt et al., 1990). 
The ultrastructure of TJ at the endothelial junctions in the brain was first described in 1967 
using electron microscopy (EM) (Reese and Karnovsky, 1967). Today it is known that the TJ 
consist of transmembrane linker proteins and cytoplasmic proteins. Three families of 
transmembrane linker proteins are known: (i) claudins, (ii) TJ-associated MARVEL (MAL and 
related proteins for vesicle trafficking and membrane link) proteins, including occludin 
(Furuse et al., 1993), tricellulin (Ikenouchi et al., 2005) and marvelD3 (Steed et al., 2009) and 
(iii) immunoglobulin superfamily membrane proteins, including junctional adhesion 
molecules (JAM)-A, JAM-B and JAM-C (Aurrand-Lions et al., 2001) and ESAM (endothelial 
cell-selective adhesion molecule) (Nasdala et al., 2002). These transmembrane proteins 
interact via their cytoplasmic domains with intracellular proteins, such as zonula occludens 1 
(ZO1), ZO2 and ZO3, which connect the TJ to the actin cytoskeleton and form the backbone 
of the TJ plaque (Gumbiner et al., 1991; Stevenson et al., 1986). In addition numerous 
regulatory and signaling molecules are described to be located at the intracellular TJ plaque 
including small GTPases, ZO-1-associated nucleic acid-binding protein (ZONAB) or protein 
kinase C subtypes (PKCζ and PKCλ) (Balda et al., 2003; Citi et al., 2011; Gopalakrishnan et al., 
1998; Suzuki et al., 2002; Yamanaka et al., 2001). In addition, the cell-cell contacts in the 
junctional zone are stabilized by adherens junctions (AJ) (Schulze and Firth, 1993). 
1.2.1.1 Occludin 
Occludin was the first TJ-specific transmembrane protein to be discovered. It was described 
to be localized at the TJ in chicken (Furuse et al., 1993) and later also in mammals (Ando-
Akatsuka et al., 1996). Occludin has a molecular size of about 60-65 kDa and consists of four 




coiled coil containing C-terminal tail. Its overexpression was shown to increase TEER values 
in vitro (Balda et al., 1996; McCarthy et al., 1996). However, in TJ deficient insect cells or 
mouse fibroblasts, occludin expression failed to induce de novo formation of intercellular TJ 
(Furuse et al., 1996; Furuse et al., 1998b). Furthermore, occludin deficient mice show an 
intact TJ morphology in intestinal epithelial cells, both by immunofluorescence and freeze 
fracture EM. No difference between wild type (wt) and occludin deficient mice regarding the 
electrophysiological barrier function of the intestinal epithelium was observed. However, 
occludin deficient mice display abnormalities in several tissues, like chronic gastritis, 
calcification of the brain and atrophy of the testis (Saitou et al., 2000). These data indicate 
that occludin is not the central TJ protein to seal the paracellular cleft. However, a regulatory 
and accessory function for occludin in TJ formation and physiology is assumed. It was shown 
that occludin is targeted by several kinases (Chen et al., 2002; Sakakibara et al., 1997; 
Tsukamoto and Nigam, 1999; Wong, 1997). For example VEGF-induced occludin 
phosphorylation was demonstrated to result in increased permeability (Harhaj et al., 2006) 
which was also correlated with occludin degradation in a model of retinopathy (Murakami et 
al., 2009). Another example is the Src mediated occludin phosphorylation after focal 
ischemia, also resulting in increased permeability (Kago et al., 2006; Takenaga et al., 2009). 
1.2.1.2 Claudins 
Claudins constitute the backbone of the TJ strands. To date 27 members of the claudin 
family have been identified (Mineta et al., 2011). Like occludin, claudins consist of four 
membrane spanning domains, two extracellular loops and cytosolic N- and C-terminal 
domains and have a molecular size of 20-27 kDa (Furuse et al., 1998a; Morita et al., 1999). 
Claudins are expressed in a tissue-specific manner. They do not only function in the sealing 
of the paracellular cleft but also form ion-selective pores with a specific pore size and charge 
selectivity in different tissues. One example is claudin-16 which forms selective pores for the 
reaborption of Mg2+ and Ca2+ ions in the kidney and is therefore selective for bivalent, but 
not monovalent cations (Simon et al., 1999). 
In the brain, claudin-5 was shown to be the key contributor to TJ formation and BBB 
integrity. In addition, claudin-3 and -12 are localized at the TJ of the BBB, however with 
significantly lower expression levels (Daneman et al., 2010a; Liebner et al., 2000b; Nitta, 
2003; Ohtsuki et al., 2008; Wolburg et al., 2003). The localization of claudin-1 at the BBB has 
been controversial as certain Ab show cross-reactivity with claudin-3 (Nitta, 2003; Wolburg 




Numerous studies have demonstrated claudin-5 to be important in the sealing of the BBB. 
Indeed, in vitro studies showed that exogenous expression of claudin-5 enhances barrier 
properties in rat brain EC (Ohtsuki et al., 2007) while the disruption of claudin-5 increases 
the paracellular permeability (Luissint et al., 2012). Using knockout mice, claudin-5 was 
shown to be crucial for the sealing of the BBB to small molecules of < 800 Da. Interestingly, 
TJ appeared normal on the ultrastructural level in claudin-5 deficient mice, indicating that 
other TJ proteins can partially compensate for the loss of claudin-5. Using 
immunohistochemistry claudin-12 and ZO1 were demonstrated to be located at the TJ. 
Claudin-5 deficient mice die within 10 h after birth although the cause of death is not known 
(Nitta, 2003). 
Claudin-3 was shown to be important for TJ formation at the level of the blood-CFS barrier. 
Its expression levels are higher in the choroid plexus than in brain capillaries (Kooij et al., 
2013; Kratzer et al., 2012). Claudin-3 deficient mice were reported to be viable and fertile 
and to have no apparent phenotype. However, enhanced blood-CSF permeability was 
detected using Evans blue as a tracer molecule, which indicates an important role for 
claudin-3 in the formation of the blood-CSF barrier. Additionally, when challenged, these 
mice displayed an earlier EAE disease onset and exacerbated disease course compared to wt 
mice (Kooij et al., 2013). 
1.2.2 Development and maintenance of the BBB 
The development and maintenance of the BBB is dependent on cellular and non-cellular 
components which were shown to interact with EC and form the so called neurovascular 
unit (NVU, Figure 2). The NVU comprises EC, astrocytes, pericytes (at the level of capillaries), 
vascular smooth muscle cells (at the level of arteries), the basal lamina, neurons and 
microglia (Abbott et al., 2006). Together these cells compose a dynamic structure that is able 
to respond to peripheral or central cues by the regulation of the permeability of the BBB and 
the expression of TJ and transporter molecules. During inflammation the NVU can also 






Figure 2: Cellular and structural components of the neurovascular unit 
The BBB is composed of brain EC, a surrounding basal lamina, pericytes and astrocytic endfeet. These 
components are in close contact. Astrocytic and pericytic signaling where shown to be crucial for the 
development and maintenance of the BBB phenotype of brain EC. In addition, the broader term NVU includes 
other brain cells such as neurons and microglia which were also shown to directly or indirectly interact with EC. 
 
Furthermore, the interplay between the components of the NVU is essential for the 
development and maintenance of the BBB. The BBB develops during embryogenesis, and its 
characteristics are fully developed by birth. During embryonic development mesoderm 
derived angioblasts were shown to invade the head region where they form the perineural 
vascular plexus, a vascular network that covers the neural tube. Subsequently, vascular 
sprouts start to invade the neural tube originating from the perineural vascular plexus and 
thereby form the CNS vasculature (Bar, 1983; Feeney and Watterson, 1946; Strong, 1964). 
The induction of BBB defining properties in the vasculature is dependent on the cellular and 
molecular crosstalk between the sprouts and the neuroectoderm. This was demonstrated in 
early quail to chicken transplantation studies. When non-vascularized neural tissue from 
quail embryos was transplanted into the coelomic cavity of chick embryos, abdominal host 
vessels vascularized the grafted tissue and adopted a BBB phenotype. In contrast, brain 
vessels vascularizing transplanted mesodermal tissue did not develop BBB characteristics 
(Stewart and Wiley, 1981). 
CNS angiogenesis depends mainly on two signaling molecules: VEGF and Wnt both of which 
are produced by neural progenitor cells. In the brain VEGF is secreted by neural progenitor 
cells in the subventricular neuroectoderm resulting in the formation of a VEGF concentration 




has a crucial role in the angiogenesis in all tissues, the Wnt/ß-catenin pathway is specific for 
the angiogenesis in the CNS. Mice deficient of the two Wnt ligands Wnt7a and Wnt7b die 
around embryonic day 12.5 and present severe hemorrhage and abnormal vessel 
morphology (Daneman et al., 2009; Stenman et al., 2008). In addition, the Wnt/ß-catenin 
pathway plays a role in BBB maturation, i.e. TJ formation as ß-catenin depletion in EC 
resulted in reduced expression of claudin-3 and -5. This observation was accompanied by an 
increased permeability to the tracer dye Evans blue (Liebner et al., 2008). Another factor 
implied in the maturation of the BBB is sonic hedgehog (Shh). Mouse embryos deficient in 
Shh show a decreased expression of TJ proteins such as occludin and claudin-5 despite 
having normal numbers of blood vessels. Moreover, selective depletion of the downstream 
signaling protein smoothened from EC results in lower TJ protein expression and vessel 
leakage of plasma proteins (Alvarez et al., 2011). Other signaling molecules suggested to play 
a role in the maturation and differentiation of the BBB are, e.g., transforming growth factor 
ß (TGF-ß), angiopoietin 1 (Ang-1), angiotensin II (AGT-II) and apolipoprotein E (ApoE) (Dohgu 
et al., 2005; Lee et al., 2003; Nishitsuji et al., 2011; Wosik et al., 2007b).  
Cellular and molecular crosstalk between EC and brain parenchymal cells is important for the 
development of the BBB. Also in the adult brain, the CNS microenvironment appears to be 
crucial for the maintenance of the BBB as indicated by numerous in vitro studies. Once brain 
EC are isolated they lose BBB properties, resulting, e.g., in transcriptional changes and 
increased permeability (Butt et al., 1990; Demeuse et al., 2002; Lyck et al., 2009; Maxwell et 
al., 1987). Co-culture of isolated brain EC with either astrocytes, pericytes or neurons or 
combinations of these cells was shown to partly rescue their BBB phenotype. An increase in 
TEER values, reduction of permeability, induction of tighter TJ and an enhanced expression 
and polarization of transporters was observed under co-culturing conditions (Berezowski et 
al., 2004; Demeuse et al., 2002; Maxwell et al., 1987; Nakagawa et al., 2009; Nakagawa et 
al., 2007; Perriere et al., 2007; Schiera et al., 2003). 
1.2.2.1 Pericytes 
Pericytes enwrap the abluminal side of capillaries, small arterioles and venules. They are in 
close proximity to EC, only separated by the basal lamina (King and Schwyn, 1970; Movat 
and Fernando, 1964; Murakami et al., 1979). Although pericytes form a rather 
heterogeneous cell population with no distinct, pericyte-specific marker, platelet-derived 
growth factor receptor ß (PDGFR-ß) was suggested as a cell specific molecule of brain 




takes place early during angiogenesis and is mediated by the release of the PDGFR-ß ligand 
PDGF-b by nascent sprouts which results in the attraction of PDGFR-ß expressing pericytes 
(Bjarnegård et al., 2004; Enge et al., 2002; Hellström et al., 1999). PDGF-b and PDGFR-ß 
deficient mice lack brain pericytes and are embryonically lethal (Lindahl et al., 1997). 
Moreover, these mice show an increased vascular permeability and altered junctional 
architecture (Daneman et al., 2010b; Hellström et al., 2001). Additionally a direct correlation 
between pericyte coverage of capillaries and BBB permeability to tracer molecules in 
neonatal mice was observed (Daneman et al., 2010b). This indicates a role of pericytes in the 
induction of a BBB phenotype in brain EC during embryogenesis. In addition, pericyte 
signaling has been implied in the maintenance of the BBB during adulthood. Using 
genetically modified mice with significantly decreased pericyte vessel coverage, an increase 
in BBB permeability (Armulik et al., 2010; Bell et al., 2010) and age dependent reduction of 
TJ protein expression (Bell et al., 2010) were shown. However, the molecular pathways by 
which pericytes participate in the maintenance of the BBB are still unknown. 
1.2.2.2 Astrocytes 
Astrocytes perform multiple functions in the brain including the uptake and recycling of 
neurotransmitters, the nutrition of neurons, the regulation of extracellular ion levels, the 
participation in immune reactions and the maintenance of the BBB. Astrocytic endfeet 
encircle the abluminal side of CNS vessels and have a close physical association with EC. 
Therefore, a possible regulatory function of astrocytes in the development and maintenance 
of the BBB has been assumed. Numerous mechanisms by which astrocytes might regulate 
the permeability of the BBB have been described. The release of src-suppressed C-kinase 
substrate (SSeCKS) by astrocytes was shown to increase during BBB maturation which 
resulted in an enhanced TJ protein expression and a decreased BBB permeability (Lee et al., 
2003). Furthermore, astrocytes secrete Shh which binds to hedgehog receptors on EC and 
thereby increases the expression of occludin and claudin-5 (Alvarez et al., 2011). Another 
mechanism that has been proposed for the regulation of the BBB is the release of ApoE by 
astrocytes. Indeed, adult ApoE deficient mice show an increase in albumin permeability at 
the BBB (Methia et al., 2001) which progresses with age (Hafezi-Moghadam et al., 2007). 
Furthermore, the renin-angiotensin hormone system has been implied in the regulation of 
BBB permeability. Angiotensinogen (AGT) is expressed and released by astrocytes and is 
subsequently converted to the active form AGT-II which binds to its type 1 receptor (AT1) on 




BBB permeability in vitro. Conversely, AGT deficient mice show a loss of BBB integrity 
associated with disorganized occludin strands (Wosik et al., 2007b). 
Furthermore, activation of astrocytes during CNS inflammation was shown to alter their 
expression of secreted molecules, e.g., in MS or its animal model EAE. Here, the increase in 
factors released by astrocytes was shown to have both beneficial and detrimental effects on 
the integrity of the BBB and the infiltration of immune cells. Enhanced expression of Shh and 
retinoic acid resulted in protection of the BBB and endothelial immune quiescence (Alvarez 
et al., 2011; Argaw et al., 2009; Mizee et al., 2014). In contrast, enhanced expression of 
VEGF-A by astrocytes disrupted occludin and claudin-5 strands which was accompanied by 
an increased BBB permeability. Furthermore, inactivation of astrocytic VEGF-A expression 
reduced BBB breakdown, infiltration of immune cells and disease severity (Argaw et al., 
2012; Argaw et al., 2009). These experimental data were supported by the observation that 
Shh, retinoic acid and VEGF-A are upregulated in reactive astrocytes in MS lesions (Alvarez et 
al., 2011; Argaw et al., 2009; Mizee et al., 2014; Proescholdt et al., 2002). Contrarily, the 
expression of AGT was observed to be reduced in perivascular astrocytes of MS lesions 
which might be mediated by proinflammatory cytokines. As mentioned above, AGT appears 
to be important for BBB maintenance and therefore a reduction in AGT expression during 
inflammation was proposed to contribute to the dysfunction of the BBB in MS patients 
(Wosik et al., 2007b). 
1.2.3 The BBB during neuroinflammation 
During neuroinflammation two major changes are described at the BBB: (i) increases in BBB 
permeability to solutes associated with disruption of TJ and (ii) the activation of the 
endothelium contributing to recruitment and activation of immune cells. Under pathologic 
conditions immune cells such as lymphocytes, monocytes, macrophages and PMN (including 
neutrophils, eosinophils and basophils) may be recruited into the CNS. Disruption of the BBB 
integrity and subsequent increases in vascular permeability and leukocyte extravasation 
were described during CNS inflammation, e.g., in NMO, MS, cerebral malaria and stroke 
(Brown et al., 1999; Grossman et al., 1986; O'Riordan et al., 1996; Virapongse et al., 1986). In 
MS, the infiltration of leukocytes into the CNS is thought to be an early event and associated 
with increases in BBB permeability which may favor the recruitment of additional leukocytes 




The recruitment of leukocytes into the CNS is a multistep process and involves leukocyte 
rolling/tethering, arrest, firm adhesion and crawling at the endothelium and finally 
diapedesis into the parenchyma. The first step is mediated by a transient contact of 
leukocytes with the endothelium, the tethering and rolling phase. On the luminal side of the 
endothelium adhesion molecules of the selectin family (L-, E- and P-selectin) are expressed 
which are recognized by their respective ligands on leukocytes. Alternatively, 
tethering/rolling can be mediated by binding of the ligand vascular cell adhesion molecule 
(VCAM)-1 on EC to α4-integrins on leukocytes (Alon et al., 1995; Bernardes-Silva et al., 2001; 
Carvalho-Tavares et al., 2000). Subsequently, leukocytes slow down their velocity and may 
become activated by immobilized chemokines presented on the activated endothelium 
which are recognized by their G-protein coupled receptors. Intracellular signaling results in 
conformational changes of α4- and ß2-integrins on the leukocyte surface transforming from 
a low to a high affinity/avidity state (Chigaev et al., 2003; Piccio et al., 2002). Activated 
integrins in turn bind to their respective ligands on the endothelial surface, e.g. VCAM-1, 
intercellular adhesion molecule (ICAM)-1 or ICAM-2 mediating arrest, adhesion and finally 
para- or transcellular diapedesis (Berlin et al., 1995; Gorina et al., 2014; Stanimirovic et al., 
1997). Which factors favor which route of transmigration is still controversial. 
Transmigration into peripheral tissue may occur mainly via the paracellular route. However, 
when PMN encounter tight endothelial junctions like in the CNS or when ICAM-1 levels are 
high the transcellular route may be preferred (Abadier et al., 2015; Greenwood et al., 1994; 
Lossinsky et al., 1989; McMenamin et al., 1992; Raine et al., 1990; von Wedel-Parlow et al., 
2011; Wolburg et al., 2005; Yang et al., 2005). The transcellular route furthermore enables 
leukocytes to cross the endothelium without TJ disruption. Moreover, during diapedesis, a 
transmigratory cup or dome is formed by the EC surrounding the infiltrating leukocytes 
which also may minimize permeability during transmigration (Carman and Springer, 2004; 
Petri et al., 2011; Wolburg et al., 2005). 
However, under pathologic conditions the disruption of the BBB can be associated with loss 
of TJ proteins. This may be mediated, e.g., by the release of cytokines both from infiltrating 
leukocytes and perivascularly located cells such as astrocytes, pericytes or microglia. Indeed, 
leukocytes were demonstrated to release cytokines (e.g. tumor necrosis factor (TNF)-α, 
interferon (IFN)-γ, IL-6), enzymes (e.g. MMPs) and reactive oxygen species that may directly 
or indirectly facilitate BBB disruption. Receptors for TNF-α and INF-γ were both reported to 
be expressed on EC, and alterations of the cellular distribution of TJ and AJ proteins after 




Kallmann et al., 2002; Ozaki et al., 1999). A direct regulation of TJ by these cytokines at the 
BBB has been controversial. However, TNF-α and INF-γ were shown to increase the 
expression and secretion of chemokines and adhesion molecules by endothelial cells which 
may enhance leukocyte infiltration (Lombardi et al., 2009; Subileau et al., 2009; Wosik et al., 
2007a). In addition, MMPs released during inflammation may play a role in the disruption of 
the BBB. MMPs are a family of zinc-dependent endopeptidases whose major functions are 
tissue remodeling and degradation of extracellular matrix components. They are therefore 
important during development. In addition, MMPs were shown to be upregulated in various 
neurological disorders, including MS and NMO (Adair et al., 2004; Alexander et al., 2010; 
Bernal et al., 2009; Hosokawa et al., 2011; Lindberg et al., 2001; Liuzzi et al., 2000; Lorenzl et 
al., 2002). Furthermore, mice deficient in both MMP9 and MMP2 are resistant to EAE 
(Agrawal et al., 2006) while pharmacologic inhibition of MMPs results in an ameliorated EAE 
course (Gijbels et al., 1994; Hewson et al., 1995; Niimi et al., 2013). Especially MMP9 has 
been suggested to play a role in the extravasation of leukocytes into the parenchyma in 
various diseases, such as NMO, MS, stroke or traumatic brain injury (Castellanos et al., 2003; 
Horstmann et al., 2003; Montaner et al., 2003; Suehiro et al., 2004). In NMO and MS 
elevated MMP9 levels were measured in the CSF and serum of patients (Alexander et al., 
2010; Gijbels et al., 1992; Hosokawa et al., 2011; Mandler et al., 2001) as well as in the 
serum and CNS of animals with EAE (Clements et al., 1997; Kandagaddala et al., 2012; 
Kieseier et al., 1998; Nygårdas and Hinkkanen, 2002). Although the exact mechanism of BBB 
regulation by MMP9 is not known it may directly influence the permeability of the 
endothelium by the degradation of TJ proteins (Agrawal et al., 2006; Bojarski, 2004; Lischper 
et al., 2010; Liu et al., 2009; Reijerkerk et al., 2006; Yang et al., 2007). 
In addition, leukocytes may directly influence BBB permeability by adhesion mediated 
signaling. Here, ICAM-1 and ß2-integrin interaction was shown to result in intracellular 
calcium signaling, actin rearrangement, phosphorylation of AJ proteins, endothelial 
contraction and increased permeability in vitro (Durieu-Trautmann et al., 1994; Etienne-
Manneville et al., 2000; Gautam et al., 1998; Gautam et al., 2000; Turowski et al., 2008). 
Furthermore, deletion of the C-terminal ICAM-1 domain in ECs inhibited intracellular 




1.3 Aim of this thesis 
The overall aim of this work was to characterize the breakdown of the BBB in a model of 
NMO in rats and to investigate the underlying mechanisms. Specifically, we were interested 
to examine whether there is (i) a relationship between BBB breakdown and astrocyte loss, 
(ii) a correlation between BBB breakdown and the disruption of TJ and (iii) a possible role of 
immune cells in the induction of BBB permeability. Therefore, this thesis intends to answer 
the following questions: 
(i) Does the depletion of astrocytes from NMO-like lesions coincide with BBB permeability? 
Astrocytes, which are the main targets of the humoral immune response in NMO, were 
shown to play a role in the maintenance of the BBB phenotype. To investigate whether 
the loss of astrocytes in focal NMO-like lesions correlates with the induction of BBB 
permeability, time course experiments were performed using serum molecules and 
exogenous tracers as markers for BBB breakdown. Furthermore, the presence of 
pericytes in NMO-like lesions was investigated. 
(ii) Is vascular leakage associated with a disruption of TJ? 
The disruption of TJ strands between adjacent EC was demonstrated to be associated 
with the loss of BBB integrity to solutes. To evaluate TJ in NMO-like lesions, TJ molecules 
were investigated on the mRNA and protein level. In addition, the ultrastructural TJ 
morphology was assessed. 
(iii) What is the role of leukocytes for BBB disruption and NMO lesion formation? 
Infiltrating leukocytes can regulate BBB permeability upon transmigration into the CNS 
and were shown to participate in the formation of NMO-like lesions by ADCC. Therefore, 
leukocyte infiltration into NMO-like lesions was investigated. PMN were depleted to 
investigate their contribution to astrocyte depletion and BBB disruption. Using small 
molecule inhibitors, the roles of the C5a receptor and neutrophil elastase for PMN 
recruitment and BBB disruption were assessed in vivo. Furthermore, the influence of 
proteases released by PMN on the permeability of endothelial monolayers was 
investigated in vitro. 
 
MATERIALS AND METHODS 
17 
 
2 MATERIALS AND METHODS  
2.1 Materials 
2.1.1 Reagents 
Table 1: Reagents 
Reagents Source of supply 
0.9% NaCl solution B. Braun, Germany 
Acetic acid Merck Millipore, Darmstadt, Germany 
Azure II, powder Merck Millipore, Darmstadt, Germany 
BD Calibrite™ BD Biosciences, Franklin Lakes, NJ, USA 
BD FACS Shutdown Solution BD Biosciences, Franklin Lakes, NJ, USA 
BD FACSClean™ BD Biosciences, Franklin Lakes, NJ, USA 
BD FACSFlow™ BD Biosciences, Franklin Lakes, NJ, USA 
BD Perm/Wash™ BD Biosciences, Franklin Lakes, NJ, USA  
Chemically defined lipid concentrate Life Technologies GmbH, Darmstadt, Germany 
Chloral hydrate Merck Millipore, Darmstadt, Germany 
Citric acid Merck Millipore, Darmstadt, Germany 
DAB (3,3'-Diaminobenzidine) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
DAPI (4',6-diamidino-2-phenylindole) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
DDSA (2-Dodecenylsuccinic acid 
anhydride)  
Serva Electrophoresis GmbH, Heidelberg, Germany 
DePeX VWR international, Darmstadt, Germany 
Di-sodium tetraborate decahydrate 
(Borax) 
Merck Millipore, Darmstadt, Germany 
DMEM (High Glucose (4.5g/l), w/ L-
Glutamine, sodium pyruvate) 
Gibco, Life Technologies GmbH, Darmstadt, Germany 
DMP-30 (2,4,6 
Tris(dimethylaminomethyl)phenol) 
Serva Electrophoresis GmbH, Heidelberg, Germany 
DMSO (dimethyl sulfoxide) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
EBM-2 basal medium Lonza, Basel, Switzerland 
Eosin G Merck Millipore, Darmstadt, Germany 
Ethanol, absolute Merck Millipore, Darmstadt, Germany 
FCS (fetal calf serum) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Fluorescence mounting medium Dako Deutschland GmbH, Hamburg, Germany 
Forene® 100%(V/V) (Isoflurane; 1-chloro-
2,2,2-trifluoroethyldifluoromethylether) 
Abbott GmbH & Co. KG, Wiesbaden, Germany 
Formalin, 37% Merck Millipore, Darmstadt, Germany 
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Reagents Source of supply 
Giemsa’s Azur-Eosin-Methylene blue 
solution 
Merck Millipore, Darmstadt, Germany 
Glutaraldehyde, 25%, aqueous solution Merck Millipore, Darmstadt, Germany 
H2O2 (hydroxic peroxide), 30%  Merck Millipore, Darmstadt, Germany 
HCl (hydrochloric acid) Merck Millipore, Darmstadt, Germany 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid)buffer, 1 M 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Hydrocortisone Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Hydrogen peroxide, 30% solution Merck Millipore, Darmstadt, Germany 
Isopropanol Merck Millipore, Darmstadt, Germany 
Ketamine, 10% Medistar®, Ascheberg, Germany 
L-Ascorbic Acid Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Mayer’s hemalum Merck Millipore, Darmstadt, Germany 
Methylene blue Merck Millipore, Darmstadt, Germany 
Monastral blue (Copper (II) 
phthalocyaninetetrasulfonic acid 
tetrasodium salt) 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
NaOH (sodium hydroxide solution), 
1 M 
Merck Millipore, Darmstadt, Germany 
Nitric acid, 65% Merck Millipore, Darmstadt, Germany 
Osmium tetraoxide, powder Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Paraffin (Paraplast Plus®) Tyco Healthcare, Neustadt, Germany 
PBS (phosphate buffered saline), 10x Biochrom AG, Berlin, Germany 
PBS (phosphate buffered saline), sterile Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Penicillin-streptomycin (10000 U/ml 
penicillin; 10 mg/ml streptomycin) 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
PFA (paraformaldehyde), powder Merck Millipore, Darmstadt, Germany 
PLL (Poly-L-Lysin) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
PMX-53 Teva Pharmaceutical Industries Ltd, Petha Tikva, Israel 
Puromycin dihydrochloride from 
streptomyces alboniger 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Renlam ® M-1 Serva Electrophoresis GmbH, Heidelberg, Germany 
Silver nitrate Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Sivelestat sodium salt R&D Systems GmbH, Wiesbaden-Nordstadt, Germany 
Sodium carboxymethyl cellulose Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Sodium thiosulfate pentahydrate Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
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Reagents Source of supply 
ß-mercaptoethanol Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Tris (tris(hydroxymethyl)aminomethane) Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Triton® X-100 MP Biomedicals, LLC, Santa Ana, CA, USA 
Xylazine solution, 20 mg/ml Ecuphar, Oostcamp, Belgium 
Xylene Chemsolute, Th. Geyer GmbH & Co. KG, Renningen, 
Germany 
 
2.1.2 Solutions, buffers and cell culture media 
Table 2: Solutions 
Solution composition 
Chloral hydrate, 14% Distilled water 
14%          chloral hydrate 
 
Dextran, 20% solution (MW ≥450.000) 0.9% sterile NaCl solution 
20%         dextran 
FACS buffer PBS 
2%           BSA 
0.2%        sodium azide 
 
Glutaraldehyde, 3% solution 12 ml         25% glutaraldehyde  
88 ml         PBS 
 
Paraformaldehyde (PFA), 4% solution PBS 
4%            PFA  
Adjust to pH 7.4 
 
Synthetic resin 27 ml       Renlam M-1 
23 ml       DDSA 
1 ml         DMP-30 
 
 
Table 3: Cell culture buffer, media and coating materials 
Solution Composition 
0.01% PLL solution for surface coating (primary 
astrocytes) 
PBS, sterile 
0.01%                PLL 









Astrocyte culture medium DMEM 
10%  FCS 
100 U/ml penicillin 
0.1 mg/ml          streptomycin 
 
RBEC density centrifugation medium DMEM 
20%                    BSA 
 
RBEC digestion buffer DMEM 
100 U/ml penicillin 
0.1 mg/ml          streptomycin 
10 mM  HEPES 
1 U/ml  Dispase II 
10 U/ml DNase I 
0,1 U/ml Collagenase D 
 
RBEC dissection buffer DMEM 
100 U/ml penicillin 
0.1 mg/ml          streptomycin 
10 mM  HEPES 
 
RBEC experimental medium RBEC growth medium  
140 µM              hydrocortisone 
 
RBEC growth medium EBM-2 
5%  FCS 
1%                       chemically defined lipid 
concentrate 
100 U/ml penicillin 
0.1 mg/ml          streptomycin 
5 µg/ml ascorbic acid 
10 mM  HEPES 
1 ng/ml  basic fibroblast growth factor 
 
RBEC selection medium RBEC growth medium 
4 µg/ml              puromycin dihydrochloride 
 
Surface coating for RBEC Distilled water, sterile 
50 µg/ml collagen IV 
50 µg/ml fibronectin 
Pipette thin layer into insert and air dry 
 
Abbreviations: RBEC: rat brain endothelial cells 
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Table 4: Solutions for histochemistry, immunohistochemistry and electron microscopy 
Solution Composition 
1% eosin 70%                  isopropyl alcohol 
1%                    eosin G 
Stir, filter 
Before use add 0,5% acetic acid 
 
1% HCl 1%                   HCl absolute 
70%                  ethanol 
 
10 mM citric acid buffer distilled water 
2,1 g/l               Citric acid 
Adjust to pH 6 
 
2% sodium thiosulfate solution for Bielschowsky 
silver impregnation 
distilled water 
20 g/l             sodium thiosulfate pentahydrate 
 
20% silver nitrate solution for Bielschowsky 
silver impregnation 
distilled water 
0,2 g/ml           silver nitrate 
 
 
3,3’-diaminobenzidine tetrachloride (DAB) 
working solution 
PBS 
0.5 mg/ml       DAB 
Add 20 µl 30% hydrogen peroxidase per 50 ml 
DAB solution before use 
 
Blocking buffer for immunohistochemistry PBS 
10%                  FCS 
 
Citric acid buffer, 10 mM 2.1 g             citric acid 
1 l                 distilled water 
NaOH, adjust to pH 6 
 
Developer stock solution for Bielschowsky silver 
impregnation 
100 ml            distilled water 
0.5 g               Citric acid 
20 ml              37% formalin 
2 drops           65% nitric acid 
 
Richardson’s stain 10 ml              1% Azure II 
5 ml                2% methylene blue 
5 ml                1% borax 
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2.1.3 Antibodies, enzymes and proteins 
Table 5: Primary antibodies for immunohistochemical staining 







Source of supply 
AQP4 aquaporin4/ 
water channel, 
expressed in the 
brain on 
astrocytic endfeet 
rabbit P - 1:100 Merck Millipore, 
Darmstadt, 
Germany 








1:200 AbD Serotec, 
Puchheim, 
Germany 


























rabbit C ethanol 1:100 Acris Antibodies, 




rabbit C ethanol 1:250 Acris Antibodies, 




used as marker 
for BBB 
breakdown 
rabbit P proteinase 
K 







rabbit P microwave, 
citrate 
buffer 
1:50 Dako Deutschland 
GmbH, Hamburg, 
Germany 





mouse P + C microwave, 
citrate 
buffer 
1:300 Synaptic Systems 
GmbH, Göttingen, 
Germany 






rabbit P - 1:1000 Dako Deutschland 
GmbH, Hamburg, 
Germany 
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Source of supply 








C - 1:80 Abcam, 
Cambridge, 
England 












rabbit P microwave, 
citrate 
buffer 
1:50 Paesel + Lorei 











1:500 Acris Antibodies, 













C ethanol 1:50 Cell Signaling 
Technology, Inc. 
Danvers, MA, USA 
rat IgG, 
biotinylated 
rat IgG  rat P Proteinase 
K 
1:200 GE Healthcare 
Europe GmbH, 
Freiburg, Germany 
Texas Red Texas Red Rabbit P microwave, 
citrate 
buffer 
1:200 Life Technologies 
GmbH, Darmstadt, 
Germany 
vWF von Willebrand 
Factor; specific 
for EC 
rabbit C ethanol 1:70 Abcam, 
Cambridge, 
England 
Abbreviations: P = used on paraffin embedded tissue; C = used on cryopreserved tissue and/or for 
immunocytochemistry 
 
Table 6: Secondary antibodies for immunohistochemical staining 
Secondary antibody Working dilution Manufacturer 
anti-mouse IgG, biotinylated 1:200 GE Healthcare Europe GmbH, Freiburg, 
Germany 
anti-rabbit IgG, biotinylated 1:200 GE Healthcare Europe GmbH, Freiburg, 
Germany 
anti-rat IgG, biotinylated 1:200 GE Healthcare Europe GmbH, Freiburg, 
Germany 
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Secondary antibody Working dilution Manufacturer 
Cy™2-conjugated AffiPure goat Anti-
mouse (H+L) 
1:200 Jackson ImmunoResearch Laboratories, 
Inc., West Grove, PA, USA 
Cy™3-conjugated AffiPure goat Anti-
rabbit (H+L) 
1:200 Jackson ImmunoResearch Laboratories, 
Inc., West Grove, PA, USA 
 
Table 7: Monoclonal antibodies for flow cytometry 
Specificity Fluorochrome Clone Dilution Source of supply 
CD11b Alexa Fluor 647 Ox-42 1:100 AbD Serotec, Oxford, UK 
CD4 PE-Cy5 OX-35 1.100 BD Biosciences, Franklin Lakes, 
NJ, USA 
CD45RA PE OX-33 1:100 BioLegend, San Diego, CA, USA 
CD8a PerCP OX-8 1:100 BioLegend, San Diego, CA, USA 
granulocytes PE RP-1 1:100 BD Biosciences, Franklin Lakes, 
NJ, USA  
TCR α/ß Alexa Fluor 647 R73 1:100 BioLegend, San Diego, CA, USA  
Abbreviations: CD= cluster of differentiation; Cy5=cyanine 5; PE= phycoerythrin; PerCP= peridinin chlorophyll 
protein; TCR= T cell receptor  
 
Table 8: Recombinant human antibodies for induction of focal NMO lesions in vivo 
Specificity Clone Application Source of supply 
AQP4 rAb-53 Induction of focal 
NMO lesions  
J. Bennett, Department of Neurology and 





rAb-2B4 Isotype control 
antibody 
J. Bennett, Department of Neurology and 
Ophthalmology, University of Colorado, 
Denver, USA 
 
Table 9: Sera for PMN-depletion in vivo 
Serum Application Source of supply 
anti-PMN antiserum 
(AIA51140)  
Depletion of PMN Accurate Chemical and Scientific 
Corporation, Westbury, NY, USA 
normal rabbit serum 
(AIS403) 
 Control serum Accurate Chemical and Scientific 
Corporation, Westbury, NY, USA 
 
Table 10: Proteins and enzymes 
Proteins/ enzymes Source of supply 
Albumin–fluorescein isothiocyanate conjugate Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
BSA (bovine serum albumin) SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
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Proteins/ enzymes Source of supply 
Cathepsin G from human leukocytes Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Collagen from human placenta Bornstein and 
Traub Type IV 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Collagenase D Roche Diagnostics Deutschland GmbH, 
Mannheim, Germany 
Complement sera human, lyophilized powder Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Dispase II (neutral protease, grade II) Roche Diagnostics Deutschland GmbH, 
Mannheim, Germany 
DNase I Roche Diagnostics Deutschland GmbH, 
Mannheim, Germany 
Elastase, human neutrophil Merck Millipore, Darmstadt, Germany 
ExtrAvidin®-Peroxidase Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Fibrinonectin from bovine plasma Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Fibroblast Growth Factor-Basic, human, 
recombinant expressed in E. coli 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
MMP9, active, human, recombinant Merck Millipore, Darmstadt, Germany 
Proteinase K Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Texas Red® cadaverine Life Technologies GmbH, Darmstadt, Germany 
Trypsin-EDTA (0.25% and 0.05%) Gibco, Life Technologies GmbH, Darmstadt, 
Germany 
 
2.1.4 Applied kits 
Table 11: Applied kits 
Kit Source of supply 
CytoTox-ONE™ Homogeneous Membrane 
Integrity Assay 
Promega, Mannheim, Germany 
High-Capacity cDNA Reverse Transcription Kit 
with RNase Inhibitor 
Life Technologies GmbH, Darmstadt, Germany 
Naphthol AS-D Chloroacetate (Specific Esterase) 
Kit 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
qPCR Core Kit Eurogentec Deutschland GmbH, Köln, Germany 
RNeasy Micro Kit Qiagen GmbH, Hilden, Germany 
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2.1.5 Primers for qPCR 
Table 12: TaqMan® qPCR primers  
Primer number RNA specificity Reference sequence Source of supply 
Rn00581751_s1 claudin-3 NM_031700.2 Technologies GmbH, Darmstadt, 
Germany 
Rn01753146_s1 claudin-5 NM_031701.2 Technologies GmbH, Darmstadt, 
Germany 
Rn01775763_g1 gapdh NM_017008.4 Technologies GmbH, Darmstadt, 
Germany 
Rn00580064_m1 occludin NM_031329.2 Technologies GmbH, Darmstadt, 
Germany 
2.1.6 Consumables 
Table 13: Consumables 
Consumable Source of supply 
Blaubrand® intraMARK micropipettes, 5 µl Brand GmbH, Wertheim, Germany 
Bottle top filter, 0.2 µm Sarstedt, Nuembrecht, Germany 
Cell culture dish, 60 x 15 mm Greiner bio-one, Kremsmuenster, Austria 
Cell culture flask, 75 cm² Greiner bio-one, Kremsmuenster, Austria 
Cell culture plate, flat bottom (12 well, 96 well) Greiner bio-one, Kremsmuenster, Austria 
Falcon 12 well permeable support companion 
plate 
Corning, Corning, NY, USA 
Falcon permeable support for 12 well plate with 
0.4 µm transparent PET membrane 
Corning, Corning, NY, USA 
MMI IsolationCaps, diffuse,  0.5 ml Molecular Machines & Industries GmbH, Eching, 
Germany 
MMI MembraneSlides, RNAse free Molecular Machines & Industries GmbH, Eching, 
Germany 
Needles BD Biosciences, Franklin Lakes, NJ, USA 
Syringes BD Biosciences, Franklin Lakes, NJ, USA 
Tubes (50 ml, 15 ml, 2 ml, 1.5 ml, 0.5 ml, 0.2 ml)  Sarstedt, Nuembrecht, Germany 
 
2.1.7 Technical devices 
Table 14: Technical devices 
Device Source of supply 
BD FACSCalibur™ BD Biosciences, Franklin Lakes, NJ, USA 
BX51 Olympus light microscope equipped with 
DP71 digital and XM10 monochrome camera  
Olympus, Hamburg, Germany 
Cellstar incubator Nunc GmbH & Co. KG, Wiesbaden, Germany 
Centrifuge 5415 R Eppendorf, Hamburg, Germany 
Centrifuge 5810 R Eppendorf, Hamburg, Germany 
Cryotome CM3050 Leica, Wetzlar, Germany 
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Device Source of supply 
EM10B electron microscope Carl Zeiss Microscopy GmbH, Oberkochen, 
Germany 
EVOM² Epithelial Voltohmmeter, STX2 electrode World Precision Instruments Germany GmbH, 
Berlin, Germany 
iCycler iQ™5 Bio-Rad Laboratories GmbH, München, Germany 
Leica Ultracut UCT Leica, Wetzlar, German 
Microtome Leica, Wetzlar, Germany 
Microwave Bosch, Gerling-Schillerhohe, Germany 
NanoDrop ND-1000 Peqlab, VWR International GmbH, Erlangen, 
Germany 
Stereotactic device Stoelting Co, Wood Dale, IL, USA 
T3 Thermocycler Biometra, Germany 
Tecan Safire plate reader Tecan Group Ltd., Männedorf, Switzerland 
TP 1020 (tissue processor) Leica, Wetzlar, Germany 
 
2.1.8 Software 
Table 15: Software 
Software Application Source of supply 
ImageJ 1.47d Measurements of lesion size 
and tracer extravasation 
National Institutes of Health, 
Bethesda, Maryland, USA 
GraphPad Prism 5.01 Statistical analysis 
Graphs 
GraphPad software Inc., La 
Jolla, CA, USA 
 
2.2 Human neuromyelitis optica (NMO) tissue 
Biopsy or autopsy central nervous system (CNS) tissue from seven anti-AQP4 seropositive 
NMO or NMO spectrum disorder patients was analyzed to investigate the type and extent 
immune cell infiltration. In 5/7 patients, brain or spinal cord biopsies were taken for 
diagnostic reasons to exclude lymphoma, astrocytoma or infection. Additionally, autopsy 
material from two patients was included in this study. Astrocyte-depleting and 
demyelinating lesions compatible with NMO or NMO spectrum disorder was confirmed by 
immunohistochemistry in these patients. Loss of AQP4 and GFAP positive cells was observed 
in macrophage-rich areas. Inflammatory areas also presented with demyelination and 
relative axonal preservation and were therefore consistent with early NMO lesions. Immune 
cell infiltration was investigated in HE (PMN infiltration), MRP14 (PMN/early monocytes), 
KiM1P (CD68, macrophages/activated microglia) and CD3 (T cells) immunohistochemistry. 
The studies on human tissue were approved by the local ethics committee (14/5/03). 




Table 16: Clinical data of patients with anti-AQP4 seropositive NMO or NMO spectrum disorder 
Patient 
no. 




CNS involvement lesions studied 
1 B 37/f 9 RR Brain, spinal 
cord, optic nerve 
Occipital brain lesion 
2 B 31/f 5 RR Brain, spinal 
cord, optic nerve 
Parietal brain lesion 
3 B 57/m 10 RR Brain, spinal cord Parietal brain lesion 
4 B 67/f < 1 ns Brain Parietal brain lesion 
5 B 45/f 2 RR Spinal cord spinal lesion 
6 A 77/f 24 RR Brain, spinal 
cord, optic nerve 
spinal lesion 
7 A 72/m 0.75 RR Brain, spinal cord spinal lesion 
Abbreviations: A = autopsy, B = biopsy, f = female, m = male, RR = relapsing remitting, ns = not specified 
2.3 Animals 
For in vivo experiments, adult female inbred 2-3 month old Lewis rats (180-245 g) were 
purchased from Charles River (Sulzfeld, Germany). 
For isolation of astrocytes and endothelial cells newborn Wistar rats were used on postnatal 
day 0 (P0) or P17, respectively. They were obtained from the in-house breeding facility. 
Animals were kept in cages with up to 5 animals each on a 12/12 h light/dark cycle at 
constant temperature and humidity with access to food and water ad libitum. Before each 
experiment, the animals were allowed to adapt to the new environment for 7 days. All 
animal experiments were conducted in accordance with the European Communities Council 
Directive of 24 November 1986 (86/EEC) and were approved by the Government of Lower 
Saxony, Germany (12/0964). 




2.4.1 Animal experiments 
2.4.1.1 Induction of focal NMO-like lesions in rats 
NMO-like lesions in rats were induced by intracortical injection of a human recombinant 
NMO-Ab, directed against AQP4, together with complement. The NMO-Ab was generated in 
the laboratory of Jeffrey Bennett (Department of Neurology and Ophthalmology, University 
of Colorado, Denver, USA). Briefly, cerebrospinal fluid (CSF) plasma cells were isolated from 
an NMO patient after a first clinical attack. The paired heavy- and light-chain sequences from 
a single plasma cell clone were reconstructed to create AQP4-specific recombinant human 
IgG1 monoclonal antibodies (Bennett et al., 2009). For the induction of focal NMO-like 
lesions the recombinant anti-AQP4 Ab 53 (rAB-53; from now on referred to as NMO-Ab) was 
used. A similarly produced non-CNS antigen specific recombinant human IgG1 antibody 
directed against measles virus nucleocapsid protein (rAb 2B4; designated in the following 
control-(ctrl-)Ab) served as a control. 
To induce focal NMO-like lesions, female Lewis rats were anesthetized by intraperitoneal 
(i.p.) injection of ketamine (60 mg/kg body weight) and xylazine (8 mg/kg body weight). 
After loss of consciousness and pedal reflexes, a rostro-caudal cut was performed to gain 
access to the skull. The head of the animal was fixed in a stereotactic device and a small hole 
was drilled through the skull, 1 mm caudally and 2 mm laterally to the bregma. When only a 
thin layer of bone was left, a small hole was made using a microdissection knife in order to 
avoid damage to the brain. Using a finely calibrated glass capillary, 1 µl antibody mixture was 
slowly injected into the cortex. This mixture contained 2.5 mg/ml Ab (either NMO-Ab or ctrl-
Ab), 15 U/ml human complement and the tracer dye Monastral Blue. After injection, the 
capillary was carefully removed and the skin was sutured. To provide analgesia 0.03 mg/kg 
buprenorphine (Temgesic©) was injected i.p. directly after surgery, which was repeated 
after 6 h and 12 h. 
2.4.1.2 Assessment of blood brain barrier (BBB) permeability 
In order to assess the integrity of the BBB, the extravasation of the endogenous marker 
molecules IgG and fibrinogen was investigated by immunohistochemical staining. 
Additionally, experiments applying exogenous tracers were performed. Therefore, two 
differently sized, lysine-fixable marker molecules were used: fluorescein isothiocyanate 
(FITC)-albumin (70 kDa) and Texas Red® cadaverine (690 Da). Rats were intravenously (i.v.) 
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injected either with 1 ml of a 10 mg/ml FITC-albumin solution (dissolved in saline) 40 min 
before perfusion, or 1 ml of a 5 mg/ml Texas Red cadaverine solution (dissolved first in 40 µl 
DMSO, and then filled up to 1 ml with saline solution) 50 min before perfusion. 
2.4.1.3 Depletion of polymorphonuclear cells (PMN) in rats 
For the depletion of blood PMN in rats rabbit anti-PMN antiserum (Accurate Chemical and 
Scientific Corporation) was used. Control rats received normal rabbit serum (Accurate 
Chemical and Scientific Corporation). To deplete PMN 1 ml/kg body weight anti-PMN 
antiserum or normal serum (filled to 2 ml with saline) was injected i.p. 18 h prior and directly 
after intracerebral injection of NMO- or ctrl-Ab. To verify the efficiency of PMN depletion, 
blood samples were taken twice from the animals: before PMN depletion and at 6 h after 
lesion induction when the animals were sacrificed. Blood smear samples were analyzed by 
Giemsa staining. Therefore, air dried blood smears were incubated in a 1:5 dilution of 
Giemsa’s azur-eosin-methylene blue solution for 40 min. Subsequently, the staining was 
differentiated in 1% HCl (in distilled water) and the smear was dehydrated and mounted. 
Differential cell counts were performed using light microscopy (400 x magnification). In each 
slide, 300 cells were counted and the percentage of PMN was calculated. 
In addition, the effect of the treatment with anti-PMN antiserum on PMN, B-cells, T-cells and 
monocytes/macrophages was investigated using flow cytometry. Flow cytometric analysis 
was performed by Michael Haberl (Department of Neuroimmunology, Institute for Multiple 
Sclerosis research, Göttingen). Blood samples were obtained by cardiac puncture once the 
animals were sacrificed, and diluted 1:1 with PBS. Subsequently, 0.75 volumes 20% dextran 
(≥ 450 kDa) were added to the blood/PBS mixture and incubated at room temperature (RT) 
for 30 min in order to allow for the aggregation of erythrocytes at the bottom of the tube. 
The leukocyte-rich plasma was then transferred to a new tube and centrifuged at 1200 rpm 
for 5 min. The supernatant was discarded, the pellet was washed with PBS and centrifuged 
again. Subsequently, the cell pellet was resuspended in FACS buffer. 100 µl of the cell 
suspension were used for each staining. Prior to granulocyte labeling, cells were fixed with 
2% PFA for 20 min, centrifuged, washed with FACS-buffer and centrifuged again. The cells 
were then permeabilized by resuspension of the cell pellet in 1x BD Perm/Wash™ buffer, 
incubated for 30 min on ice and washed twice with FACS-buffer. For staining of CD4 T cells, 
CD8 T cells, B cells and myeloid cells, no pretreatment was needed. Subsequently, Ab were 
diluted 1:100 in FACS buffer, added to the cells and incubated on ice in the dark for 30 min. 
The following Ab were used: granulocytes: RP-1; CD4 T cells: TCR α/ß and CD4; CD8 T cells: 
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TCR α/ß and CD8a; B cells: CD45RA; myeloid cells: CD11b. Cells were washed twice in FACS 
buffer and the cell pellet was resuspended in 100 µl FACS buffer. Finally, 50 µl of BD 
Calibrite™ beads (20x104 beads/ml) were added to the suspension and cells were counted 
until a minimum 1000 bead events were recorded using the BD FACSCalibur. 
2.4.1.4 Pharmacological inhibition of the complement component 5a receptor 
(C5aR) 
To inhibit C5aR mediated signaling, the small molecule C5aR antagonist PMX-53 was used. 
PMX-53 was dissolved in distilled water at a concentration of 10 mg/ml and then further 
diluted in normal sterile saline (0.9%) to a final concentration of 0.2 mg/ml. 
Animals were treated once i.v. with 1 mg/kg body weight PMX-53 or vehicle 3 h after focal 
intracerebral injection of NMO-Ab and human complement. 6 h after focal injection rats 
were perfused and brains were prepared for histological analysis. 
2.4.1.5 Pharmacological inhibition of neutrophil elastase 
For inhibition of the neutrophil elastase (NE), the competitive NE inhibitor Sivelestat sodium 
salt hydrate was used. Sivelestat was dissolved to a final concentration of 20 mg/ml in water. 
Rats were injected i.p. with 50 mg/kg body weight Sivelestat or vehicle 3 h after NMO-like 
lesion induction. Rats were perfused 6 h after intracerebral injection of NMO-Ab and human 
complement, and brains were processed for histological investigation. 
2.4.1.6 Perfusion of animals 
In order to preserve the tissue morphology for histological analyzes and to remove the blood 
from the vasculature, animals were perfused transcardially. Rats were anesthetized by i.p. 
injection of a lethal dose of 14% chloral hydrate. After the animal was deeply sedated and 
had lost the pedal and corneal reflexes, the thorax was opened. The perfusion was 
performed via the left heart ventricle.  
For histological evaluations, animals were perfused with PBS followed by 4% PFA. 
Subsequently, the brain, spleen and liver were collected in a falcon tube containing 4% PFA 
and were post-fixed for an additional 48 h at 4°C. The brain was then washed with PBS, 
dissected into 2-4 mm thick coronal sections close to the injection site marked with 
Monastral blue and washed again with water. Spleen and liver were processed in the same 
way and served as ctrl tissue in the same paraffin block. For paraffin embedding, the tissues 
were gradually dehydrated via alcohol, xylene and in the end embedded in paraffin using the 
automated tissue processor TP 1020 over night. 
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For RNA extraction and cryo-tissue preparation the perfusion was performed with sterile PBS 
only. After PBS perfusion the brain was removed, trimmed near the injection site and placed 
in a drop of Tissue-Tek® on a cork plate. Subsequently, the tissue was frozen in liquid 
nitrogen-cooled isopentan and stored at -80°C. 
2.4.2 Cell culture 
2.4.2.1 Isolation and purification of primary rat brain endothelial cells (RBEC) 
and measurement of the transendothelial resistance (TEER) 
Primary RBEC were isolated based on a modified protocol published by Joan Abbott and co-
workers in 2006 (Abbott et al., 2006). For the isolation, 17 days old Wistar rats were used. 
Rats were deeply anesthetized with isoflurane and decapitated. Brains were removed and 
directly transferred into dissection buffer in which they were stored on ice until further 
processing. All the following steps were performed under sterile conditions in a laminar flow 
hood. From each brain, the cerebellum, the olfactory bulbs and the optic nerves were 
removed, and both hemispheres were separated. One hemisphere was transferred to 
Whatman filter paper, the midbrain was removed, and the brain was folded open in order to 
remove the white matter (WM) and meninges. Subsequently the grey matter (GM) tissue 
was collected and transferred to a new Petri dish. The GM was cut into small pieces and 
transferred to a new tube containing dissection buffer and stored on ice. After centrifugation 
(800 x g, 4°C, 7 min) 7 ml of digestion solution containing Collagenase D, Dispase and DNase I 
was added to the pellet. The tissue was digested at 37°C for 30 min under constant agitation 
and then homogenized by pipetting. The suspension was centrifuged, the supernatant was 
aspirated and 20 ml of ice cold DMEM with 20% BSA was added. The pellet was thoroughly 
resuspended and centrifuged at 1000 x g for 20 min at 4°C. After centrifugation the upper 
phase contains myelin, oligodendrocytes, neurons and microglia, while microvessels can be 
found as a pellet at the bottom of the tube. The supernatant was discarded and the 
microvessels were washed once with dissection buffer and subsequently resuspended in 3 
ml digestion buffer. After an additional digestion time of 20 min at 37°C the cells were 
centrifuged. The pellet was resuspended in selection medium containing puromycin in order 
to remove contaminating non-P-glycoprotein-expressing cells (Perrière et al., 2005). RBEC 
were seeded in 12 well inserts (PET membrane, 0.4 µm pore size) precoated with collagenIV 
and fibronectin and placed in a CO2 incubator (5% CO2, 37 °C). 
After incubation for 3 d, selection medium was replaced with normal growth medium. The 
medium was replaced every other day and exchanged by experimental medium containing 
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hydrocortisone once the RBEC layer had reached 90% confluency. Cells were directly used 
for experiments when they reached TEER values of around 40 Ω*cm². 
TEER measurements are an important readout to assess the integrity of the RBEC 
monolayer. It represents the permeability of tight junctions (TJ) to sodium ions. High TEER 
values represent an impermeable monolayer. TEER was measured using the EVOM2 
resistance meter (World Precision Instruments) with STX-2 electrodes, where one electrode 
is placed in the apical and the other one in the basolateral compartment. The resistance 
measured was then expressed relative to the surface area of the insert (Ω*cm²). The TEER 
values of coated cell-free inserts (140-155 Ω*cm²) was subtracted from the values of the 
monolayers. 
To ensure that treatment with puromycin removed all contaminating cells from the RBEC 
culture, initial qPCR for AQP4 (astrocytes), CD11b (microglia), α-SMA and PDGFRß 
(pericytes), and immunocytochemistry for endothelial cell markers (vWF, occludin, claudin-3, 
claudin-5) was performed. qPCR and immunohistochemistry showed no contamination by 
other cells. 
2.4.2.2 Isolation and purification of primary rat astrocytes 
Primary rat astrocytes were isolated from newborn Wistar rats (P0-P1). Rats were 
decapitated, the brain was isolated and transferred into a Petri dish containing HBSS buffer 
(37°C). Subsequently, the meninges were removed with forceps to prevent meningeal 
fibroblasts to interfere with the glial cell growth. Brains were digested in 0.25% Trypsin-EDTA 
solution for 20 min at 37°C. Then the cells were washed once with HBSS. Subsequently, 
DMEM containing 10% FCS and 1% P/S was added to the tissue pellet and the tissue was 
dissociated by pipetting. Cells were seeded in PLL coated falcon flasks and grown for 10 to 14 
d in an incubator (5% CO2, 37°C) with medium changes every 2-3 d. When the mixed cell 
culture containing astrocytes, oligodendrocytes and microglia reached 100% confluency, the 
loosely sitting oligodendrocytes and microglia were removed by vigorous shaking of the 
flasks. The supernatant was discarded, while astrocytes stayed firmly attached to the plastic 
surface. Astrocytic cultures were used maximally for 3 weeks to avoid loss of primary 
phenotype. 
2.4.2.3 Co-culture of RBEC and astrocytes as in vitro model of the BBB 
In order to assess the indirect influence of astrocytes on RBEC, cells were co-cultured in a 12-
well transwell system. Astrocytes were plated in a 12-well cell culture plate (basolateral 
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compartment) containing astrocyte medium. At the same time, RBEC were seeded in inserts 
(apical compartment). When astrocytes reached 100% confluency, inserts with a confluent 
RBEC monolayer were transferred into the 12-well plate containing astrocytes. Astrocyte 
medium was replaced by RBEC experimental medium. TEER was measured daily for 7 d in 
triplicates. 
2.4.2.4 Incubation of RBEC monolayers with proteases and assessment of 
cytotoxicity 
To investigate the direct influence of neutrophil proteases on RBEC, NE (6 µg/ml), cathepsin 
G (0.4 U/ml) or active matrix metalloproteinase 9 (0.5 µg/ml) were added directly to the 
apical compartment of a transwell system containing RBEC. Experiments were performed in 
triplicates. TEER was measured before treatment and after 60 and 120 min. Subsequently, 
cells were fixed with 100% ethanol for immunocytochemical analysis. 
To exclude a cytotoxic effect of neutrophil proteases on RBEC the CytoTox-ONE™ 
Homogeneous Membrane Integrity Assay (Promega) was used according to the 
manufacturer’s instructions. It is based on the release of lactate dehydrogenase from dying 
cells with a leaky cell membrane. The lactate dehydrogenase-measurement was performed 
after 2 h of treatment with proteases using 100 µl of the supernatant from the apical 
compartment. Supernatant of lyzed RBEC served as positive control as described in the 
manufacturer’s protocol. 
2.4.2.5 Immunocytochemcial staining of RBEC 
To investigate TJ expression and localization in the isolated RBEC, cells were grown on 
coverslips. After reaching confluency, they were washed once with warm PBS, transferred 
into precooled 100% ethanol and fixed at -20°C for at least 30 min. Coverslips were washed 3 
times with PBS and incubated with blocking buffer (PBS with 10% horse serum and 1% BSA) 
for 20 min. Primary antibody diluted in blocking buffer was added to the coverslips for 1 h. 
RBEC were immunolabeled for the TJ molecules occludin (1:50), claudin-3 (1:100), claudin-5 
(1:300) and vWF (1:100) (Table 5). Cells were washed 3 times with PBS and subsequently 
incubated with a fluorescently labeled secondary antibody (Table 6) diluted in blocking 
buffer for 30 min. Cells were washed and the nuclei were stained using 4',6-diamidino-2-
phenylindole (DAPI, 1:10000 in PBS). After a last washing step coverslips were rinsed in 
distilled water and mounted on glass slides using fluorescence mounting medium. 




2.4.3.1 Cutting, deparaffinization and dehydration of histological paraffin-
embedded sections 
Paraffin blocks were cut into 1-2 µm thick sections using a sliding microtome, and were then 
mounted on glass slides. For identification of the injection sites, sections were checked for 
traces of Monastral blue in the tissue. 
Prior to the staining procedure, sections were gradually deparaffinized. Therefore, the 
paraffin was melted for at least 1 h at 56°C. Subsequently, the sections were first delipidized 
and then rehydrated by consecutive immersion in the following solutions: xylene (four times 
for 5 min), isoxylene (once for 2 min), 100 % isopropyl alcohol (twice for 3 min), and once in 
90 %, 70% and 50% isopropyl alcohol for 3 min each, and in the end washed with distilled 
water. 
After the staining, sections were again dehydrated in reverse order to the deparaffinization 
procedure and mounted in DePex medium. 
2.4.3.2 Histochemical stainings 
2.4.3.2.1 Hematoxylin and eosin staining (HE) 
For a general overview of the tissue with regard to inflammation and apoptosis HE staining 
was performed. The first component of the staining is hematoxylin, a basic dye which colors 
basophilic structures (particularly the DNA in the nucleus and the rough endoplasmic 
reticulum) with a blue-purple hue. The second component is the alcohol-based acidic eosin 
that stains eosinophilic structures like proteins bright pink. For staining, the sections were 
deparaffinized, washed and incubated in Mayer’s hemalum for 8 min. Then slides were 
washed with water, briefly differentiated in 1% HCl and blued for 10 min in running tap 
water. Subsequently, the slides were stained with 1% eosin for 6 min, washed with distilled 
water, dehydrated and mounted. 
2.4.3.2.2 Bielschowsky silver impregnation 
In order to ensure that the stereotactic injections into the brain were not destroying the 
surrounding tissue reflected by axonal destruction and tissue necrosis, Bielschowsky silver 
impregnation was used. It stains nerve fibers and pathological deposits black. Sections were 
deparaffinized and incubated in 20% silver nitrate (in distilled water) for 20 min and 
subsequently transferred into a cuvette with distilled water. Then 32% ammonium 
hydroxide was added dropwise into the 20% silver nitrate solution until the resulting 
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precipitations were cleared. Slides were returned into the cuvette containing silver nitrate 
and ammonium hydroxide and incubated in the dark for 15 min. Slides were then placed in 
50 ml distilled water containing three drops of ammonium hydroxide. Now 10 drops of 
developing solution were added to the silver nitrate and ammonium hydroxide solution and 
slides were briefly developed. When the desired staining intensity was reached, the reaction 
was stopped in distilled water. Slides were then incubated for 2 min in 2% sodium 
thiosulfate, rinsed, dehydrated and mounted. 
2.4.3.2.3 Chloroacetate esterase enzyme histochemistry (CAE) 
CAE stain (also called Leder stain) takes advantage of the enzymatic activity of “specific 
esterase”, an enzyme found in cells of the granulocyte lineage and was therefore used to 
detect neutrophils in the brain. In the naphthol AS-D chloroacetate kit (Sigma) that was 
used, naphthol AS-D chloroacetate is enzymatically hydrolyzed. Thereby a naphtol 
compound is liberated and couples with a diazonium compound, leading to the formation of 
bright pink deposits at sites of enzymatic activity. 
CAE staining was performed according to manufacturer’s instruction. Briefly, the slides were 
deparaffinized, rinsed in distilled water and preheated in PBS at 37°C for 1 h. Then the 
working solution was prepared, consisting of 2% sodium nitrite, 2% Fast Corinth salt, 10% 
TrizmalTM buffer and 2% naphtol AS-D chloroacetate. Slides were then incubated in the 
working solution at 37°C for 2 h and washed with distilled water. Subsequently they were 
briefly counterstained in Mayer’s hemalum, washed and mounted using Aquamount. 
2.4.3.3 Immunohistochemistry 
2.4.3.3.1 Antigen retrieval of paraffin embedded tissues 
Due to fixation of the tissues with PFA, antigens in the sections can be masked. This can 
prevent the primary Ab binding to the antigen. Therefore we used different methods to 
unmask the epitopes, which were determined separately for each antibody and are listed in 
Table 5. 
For heat-induced antigen retrieval 10mM citric acid, 1 mM Tris-EDTA or Tris-HCl solutions 
were used. The sections were heated in a microwave 5 times for 3 min, refilling first with 
water and then alternatingly with buffer and water after each cycle. After the solutions 
cooled down, buffers were replaced by water. 
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Alternatively, proteinase K-induced antigen retrieval was used. Here the slides were 
incubated at 60°C in a preheated proteinase K solution for 10 min and then washed with 
water. 
2.4.3.3.2 Cutting and fixation of frozen tissues 
Native, unfixed frozen tissues were cut into 5 µm thick sections using a cryostat and 
mounted on glass slides. They were then either stored at -80°C or further processed. To 
prevent detachment of the sections from the slides during the staining procedure, the 
sections were air-dried for at least 30 min at RT. 
Frozen tissues were fixed depending on the antibody, either for 10 min in 100% ethanol or 
30 min in 100% ether at RT (see Table 5). Subsequently sections were air-dried for 10 min, 
rehydrated for 10 min in PBS and immunostained. 
2.4.3.3.3 Immunostaining of tissues 
Immunostainings were performed in order to investigate astrocyte pathology (GFAP, AQP4), 
BBB breakdown (IgG, Fibrinogen, FITC, Texas Red), immune cell infiltration (ED1, CD3, Iba1, 
MRP14, KIM1P), blood vessel pathology (occludin, claudin-3, claudin-5, LAMγ1) or pericytes 
(PDGFRß).  
For immunohistochemical staining, the labeled streptavidin-biotin method was used. To 
block the endogenous peroxidase, pretreated frozen or paraffin embedded tissues were first 
incubated with 3% hydrogen peroxide in PBS and then washed 3 times in PBS. To block 
unspecific antibody binding, sections were treated with blocking buffer (PBS with 10% FCS) 
for 10 min. Next, the primary antibody, diluted in blocking buffer (Ab dilutions are given in 
Table 5) was added and incubated over night at 4°C. Afterwards, slides were rinsed 3 times 
with PBS. Then the corresponding biotinylated secondary antibody, diluted in blocking 
buffer, was applied to the slides for 1 h at RT (Table 6). Non-bound antibody was removed by 
washing 3 times with PBS. To amplify the signal 0.1% streptavidin horseradish peroxidase 
diluted in blocking buffer was added to the slides and incubated for 45 min at RT. After 
washing 3 times with PBS, slides were developed in a 3,3’ diaminobenzidine (DAB) solution, 
and the reaction was controlled under a microscope. The chromogen DAB acts here as a 
substrate of the peroxidase, which results in a dark brown staining. Subsequently, the slides 
were washed in distilled water and counterstained in Mayer’s hemalum for 30 s. Then they 
were washed with distilled water, differentiated in 1% HCl solution, blued in tap water for 
7 min, dehydrated and mounted as described above. 
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The indirect immunofluorescence method was used in order to stain different target 
antigens simultaneously, e.g. to evaluate the TJ of vessels within the lesions. Pretreated 
frozen tissues were washed 3 times with PBS, blocked with blocking buffer and incubated 
with the primary antibodies (Table 5) at 4°C over night. Subsequently slides were washed 3 
times in PBS and incubated with the corresponding fluorochrome-labeled secondary 
antibodies (Table 6) for 45 min at RT in the dark. After washing with PBS 3 times, nuclei were 
counterstained with DAPI (1:10000 in PBS) for 15 min at RT in the dark. Then the slides were 
washed again 3 times in PBS, rinsed once in distilled water and mounted using fluorescence 
mounting medium. 
2.4.3.4 Electron microscopy (EM) 
For assessment of the TJ morphology on the ultrastructural level, electron microscopy (EM) 
was performed. Therefore animals were perfused first with PBS and subsequently with 
4% PFA. Then the brain was removed and cut coronally at the injection site. For postfixation 
the area around the injection site was cut into three pieces (1 mm³) which were then 
transferred to 3% glutaraldehyde over night. The brain pieces were washed two times in PBS 
and incubated with 1% osmium tetroxide solution for 1 h at 4°C. Dehydration followed for 
10 min in 50% ethanol, and additional staining was performed with 0.5% uranyl acetate for 
1 h at 4 °C in the dark. The tissue was dehydrated in 70 % ethanol over night, for 10 min in 
80% and 96% ethanol and two times for 15 min in 100% ethanol. Next, for resin embedding, 
the tissue was incubated 2 times in propylene oxide for 20 min. Afterwards resin:propylene 
oxide ratios were adjusted to 1:1 and subsequently to 2:1 solution in which the tissue was 
incubated for 35 min each. Finally, the tissue was transferred into 100% resin for 1 h and 
embedded in moulds filled with araldite. 
Embedded tissues were cut in semi-thin sections of 360 – 400 nm. Sections were transferred 
to a glass slide and dried on a heating plate at 60 °C for 1 h. Semi-thin sections were stained 
with Richardson’s stain, which stains myelin in dark blue and cytoplasm in light blue, for 3 
min. Finally they were rinsed 3 times with distilled water air dried and mounted with Depex. 
According to the area of interest in the semi-thin section, the tissue blocks were trimmed 
and ultrathin sections of 70-72 nm were cut. These sections were collected on a grid, dried 
and stained with lead citrate for 10 min. 
All samples were evaluated using the electron microscope EM10B (Zeiss) and imaged. 
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2.4.4 Microdissection of lesions for mRNA expression analysis 
In order to evaluate mRNA expression of TJ genes in NMO-like lesions, laser capture 
microdissection (LCM) was performed. Therefore brain tissue of NMO- or ctrl-Ab injected 
animals was fixed in liquid nitrogen. Tissue was cut into 10 µm thick sections using a 
cryostat, mounted on polyethylene naphthalate membranes and stored at -80°C. 
In order to prevent mRNA degradation, a rapid staining protocol for astrocytes was 
established to identify the lesion outline. The tissue was first fixed in -20°C cold ethanol for 
2 min, washed briefly with PBS and then stained for 2 min with anti-GFAP-Cy3. Subsequently 
slides were washed with PBS and dipped into 100% ethanol for dehydration. LCM was then 
performed using the MMI CellCut Plus system microscope. In order to prevent RNA 
degradation LCM was performed for a maximum of 10 min. Only astrocyte depleted areas 
were extracted from NMO-Ab injected animals, while in ctrl-Ab injected animals the area 
around the injection site was isolated. The extracted tissue was directly transferred into RLT-
buffer (according to the manufacturer's instructions containing 1% ß-mercaptoethanol) and 
stored at -80°C until further processing. 
2.4.5 mRNA expression analysis 
RNA was isolated using the RNeasy Micro Kit (Qiagen) according to the manufacturer’s 
protocol for microdissected tissues. Subsequently, RNA was transcribed into cDNA using the 
High-Capacity RNA-to-cDNA™ Kit (Life Technologies) according to the manufacturer’s 
instructions. 
qPCR was performed using the qPCR core kit (Eurogentec) according to the manufacturer’s 
instructions. TaqMan Gene Expression Assays (Life Technologies) for claudin-3, -5 and 
occludin (TJ molecules) were used. The house keeping gene gapdh served as control. 
Duplicates of each probe were checked for pipetting errors which would result in high 
standard deviation (SD). Samples with a SD higher than 0.4 were excluded from further 
calculation. 
2.4.6 Morphometric analysis and data acquisition 
Astrocyte lesion size and extravasation of molecules into the parenchyma was measured 
using ImageJ. Therefore, images were taken at 40x magnification using the BX51 Olympus 
light microscope equipped with a DP71 digital camera. 
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For assessment of lesion size, areas of complete loss of AQP4 and GFAP immunoreactivity 
were measured. 
For extravasation of the endogenous tracer molecules IgG and fibrinogen and the exogenous 
tracer molecules FITC-albumin and Texas Red®-cadaverine the different channels 
(haematoxylin-DAB-3rd component) were separated using the ImageJ plugin DAB color 
deconvolution. In the brown channel (DAB) the intensity threshold for selection was set to 0-
150 and the resulting marked area was measured. For the IgG and fibrinogen time course 
the intensity threshold was adjusted to the staining intensity due to background differences 
in the different slides. 
To evaluate the percentage of blood vessels positive for TJ molecules, immunofluorescently 
labeled sections (NMO-Ab injected: claudin-3/claudin-5/occludin - LAMγ1 – GFAP; ctrl-Ab 
injected: claudin-3/claudin-5/occludin - LAMγ1) were imaged at 100x magnification using the 
BX51 Olympus light microscope equipped with a XM10 monochrome camera. The total 
number of LAMγ1-positive blood vessels was evaluated as well as the number of LAMγ1-
positive blood vessels which were immunopositive for occludin, claudin-3 or claudin-5 at the 
TJ. From this, the percentage of brain vessels with occludin, claudin-3 or claudin-5 localized 
at the TJ was calculated. 
To assess the number and density of immune cells infiltrating focal NMO-like lesions, 
immunohistochemistry for ED1 (monocytes/macrophages) and CD3 (T cells) was performed. 
In addition, CAE was used to label PMN. Cells were counted using a light microscope with an 
ocular morphometric grid. For assessment of infiltrates in animals, cells were counted in the 
whole lesion at 100x magnification. For human lesions the density of immune cells was 
evaluated by evaluating the total number of positive cells in 5 visual fields at 400x 
magnification. 
2.4.7 Statistical analysis 
Statistical analysis was carried out using the GraphPad Prism 5.01 software.  
For parametric data the independent t-test with Welch’s correction was used to compare 
two groups. To compare more than two groups, the Kruskal-Wallis test followed by Dunn’s 
multiple comparison test was performed. Pearson’s correlation coefficients were used to 
assess associations between area of FITC-albumin extravasation and number of infiltrated 





3.1 Induction of neuromyelitis optica (NMO)-like lesions results in breakdown 
of the blood-brain barrier (BBB) 
3.1.1 Time course of astrocyte depletion after focal injection of NMO-antibody 
and human complement 
To investigate the pathogenesis of lesion formation in NMO, a focal model of NMO-like 
lesions in Lewis rats was established in our group (Wrzos et al., 2014). In this model NMO-
like lesions were induced by stereotactic injection of a recombinant human NMO-antibody 
(Ab) directed against aquaporin4 (AQP4) together with human complement into the motor 
cortex of Lewis rats (Bennett et al., 2009). As a control, stereotactic injection of a similarly 
produced non-CNS antigen specific control (ctrl)-Ab together with human complement was 
performed. To investigate the development of the astrocyte depleted lesion, a time course 
study was done. Therefore, the animals were sacrificed 3 h, 6 h, 24 h, 3 d and 7 d after lesion 
induction (Figure 3 A). Lesion development was investigated using immunohistochemistry 
for the astrocyte markers glial fibrillary acidic protein (GFAP) and AQP4. 
3 h after lesion induction no confluent loss of GFAP immunoreactivity was observed (Figure 3 
B). However, damaged GFAP positive cells with retracted cell processes were detected 
(Figure 3 B, insert). Confluent, well-demarcated areas of GFAP loss were observed 6 h after 
lesion induction (area of GFAP loss: 0.26 ± 0.15 mm², Figure 3 G) in contrast to ctrl-Ab 
injected animals at the same time point (*p<0.05). Subsequently, loss of GFAP 
immunoreactivity expanded until lesions developed the maximal extent between 24 h and 
3 d (area of GFAP loss: 24 h = 1.03 ± 0.89 mm² and 3 d = 1.11 ± 0.85 mm², *p<0.5, **p<0.01, 
***p<0.001, Figure 3 G). Loss of GFAP immunoreactivity in astrocyte depleted lesions was 
confirmed by loss of AQP4 immunoreactivity 24 h after lesion induction (Figure 3 C, D). No 
loss of GFAP- (Figure 3 E) and AQP4-positive cells (Figure 3 F) was observed in animals 
injected with ctrl-Ab and human complement after 24 h. 7 d after lesion induction 91.1 % of 
the formerly astrocyte-depleted area was repopulated by GFAP positive cells (area of GFAP 





Figure 3: Injection of NMO-Ab and human complement resulted in astrocyte loss 
Schematic illustration of the experimental setup for the assessment of astrocyte lesion development over time 
(A). 3 h after focal injection of NMO-Ab and human complement, GFAP positive astrocytes were still localized 
at the injection site (B). However, GFAP positive dying cells with retracted processes were observed (B, insert). 
24 h after injection large, well-demarcated areas with loss of GFAP- (C) and AQP4 immunoreactivity (D; serial 
sections of the same lesion) were detected. No loss of GFAP (E) and AQP4 (F) positive cells was observed in 
animals with focal injection of ctrl-Ab and human complement after 24 h. The time course study revealed the 
first loss of GFAP immunoreactivity 6 h after lesion induction. Astrocyte depleted lesions reached their maximal 
extent between 24 h and 3 d. 7 d after focal injection 91.1% of the formerly astrocyte depleted lesion were 
repopulated by GFAP positive cells. No astrocyte loss was observed after injection of ctrl-Ab together with 
human complement (number of evaluated lesions: NMO-Ab/ctrl-Ab; 3h: n=5/5; 6h: n=10/10; 24h: n=10/10; 3d: 
n=6/4; 7d: n=5/5, G). Data were analyzed using Kruskal-Wallis test followed by Dunn’s multiple comparison test 
and are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001. B, E, F: Monastral blue marks the injection site. 
Dotted lines indicate area of astrocyte loss. Scale bar 100 µm 
3.1.2 Breakdown of the BBB is observed 6 h after lesion induction 
Astrocytes are in close proximity to brain endothelial cells (EC). In the adult brain astrocytic 
signaling is involved in maintaining BBB integrity (Abbott et al., 2006). To investigate 
whether astrocyte lesion development correlates with loss of BBB integrity, we investigated 
the permeability of the BBB to soluble blood-borne molecules by immunohistochemistry for 
immunoglobulin G (IgG) and fibrinogen. Both are plasma proteins with a size of 150 and 




and fibrinogen. However, under pathological conditions leakage of both proteins into the 
brain parenchyma may be observed. 
3 h after focal injection of NMO-Ab and human complement only little extravasation of IgG 
(area of extravasation: 0.05 ± 0.08 mm², Figure 4 A, D) and fibrinogen (area of extravasation: 
0.01 ± 0.01 mm², Figure 4 E, H) into the brain parenchyma was observed. However, 6 h after 
lesion induction a prominent area of the brain parenchyma immunostained positively for IgG 
(0.38 ± 0.34 mm², Figure 4 B, D) and fibrinogen (0.33 ± 0.38 mm² Figure 4 F, H). After 3 d the 
integrity of the BBB was restored, with some deposit-like immunopositive structures still 
present around the blood vessels (IgG: 0.26 ± 0.38 mm², Figure 4 C, G; fibrinogen: 0.11 ± 
0.09 mm², Figure 4 G, H). Measurement of the immunopositive area revealed a significant 
extravasation of both IgG (Figure 3 D ) and fibrinogen (Figure 4 H ) 6 h and 24 h after NMO-
lesion induction (*p<0.5). Some extravasation of both proteins was also observed in animals 
injected with ctrl-Ab together with human complement, indicating that injection of human 
complement alone may result in leakage of plasma proteins from the blood vessels. 
However, the area of extravasation in ctrl-Ab injected animals reached only 15.7% (6 h IgG), 
15.0% (24 h IgG), 21.5% (6 h fibrinogen) and 57.2% (24 h fibrinogen) of the extravasation 
measured in NMO-Ab injected animals at the same time points (Figure 4 D, H). 
 
Figure 4: Breakdown of the BBB was detected 6 h after focal injection as assessed by 
immunohistochemistry for IgG and fibrinogen 
3 h after focal injection of NMO-Ab and human complement the BBB was intact and revealed no signs of the 
blood-borne proteins IgG (A) and fibrinogen (E). 6 h later the brain parenchyma immunostained positively for 
IgG (B) and fibrinogen (F) around the injection site. 3 d after injection the BBB appeared intact with some 
immunopositive deposits of IgG and fibrinogen left around the blood vessels (C, D). Quantification of the area 




between 6 h and 3 d. Extravasation in ctrl-Ab injected animals was markedly less compared to NMO-Ab 
injected animals. Number of lesions evaluated in D: NMO-Ab/ctrl-Ab; 3h: n=5/5; 6h: n=8/7; 24h: n=8/7; 3d: 
n=6/5; 7d: n=2/1. Number of lesions evaluated in H: NMO-Ab/ctrl-Ab; 3h: n=5/5; 6h: n=9/8; 24h: n=9/7; 3d: 
n=6/5; 7d: n=2/1. Data were analyzed using Kruskal-Wallis test followed by Dunn’s multiple comparison test 
and are shown as mean ± SD. *p<0.05. Scale bar 500 µm 
3.1.3 Injection of tracer molecules indicates rapid restoration of the BBB 
within 24 h after lesion induction 
Although the extravasation of endogenous, blood-borne proteins may serve as an indicator 
for the opening of the BBB, extravasated proteins may be retained in the brain parenchyma 
after the BBB integrity is re-established. To further specify the time frame of BBB disruption, 
the BBB permeability was additionally assessed by intravenous (i.v.)-injection of exogenous 
tracer molecules before perfusion. Two lysine-fixable fluorescent tracer molecules were 
employed: fluorescein isothiocyanate (FITC)-albumin and Texas Red® cadaverine with 
molecular sizes of 70 kDa and 690 Da, respectively. Tracer molecules were injected 40 min 
(FITC-albumin) or 50 min (Texas Red® cadaverine) before perfusion. To analyze the 
permeability of the BBB, animals were stereotactically injected with NMO-Ab or ctrl-Ab and 
human complement. Subsequently, animals were sacrificed 3 h, 6 h, 24 h and 3 d (FITC-
albumin) or 6 h and 24 h (Texas Red® cadaverine) after lesion induction. The extravasation of 
the tracer molecules was assessed by immunohistochemistry against FITC-albumin and Texas 
Red® cadaverine. 
3 h after focal injection the BBB was impermeable to FITC-albumin (NMO-Ab: 0.00 ± 0.00 
mm², ctrl-Ab: 0.01 ± 0.02 mm², Figure 5 C) which confirms the observations made regarding 
the extravasation of the plasma proteins IgG and fibrinogen (Figure 4 D, H). After 6 h, 
however, a prominent extravasation of FITC-albumin (NMO-Ab: 1.03 ± 0.54 mm², ctrl-Ab: 
0.50 ± 0.30 mm², Figure 5 A, C) and Texas Red® cadaverine (NMO-Ab: 1.62 ± 0.83 mm², ctrl-
Ab: 0.84 ± 0.38 mm², Figure 5 D, F) from the vasculature into the brain parenchyma was 
observed. 24 h after lesion induction the BBB integrity was again restored as demonstrated 
by FITC-albumin (NMO-Ab: 0.00 ± 0.00 mm², ctrl-Ab: 0.00 ± 0.00 mm², Figure 5 B, C) and 
Texas Red® cadaverine antibody staining (NMO-Ab: 0.04 ± 0.07 mm², ctrl-Ab: 0.00 ± 0.00 
mm², Figure 5 E, F). This is contrary to the data we obtained from IgG and fibrinogen 
measurements and confirms that deposits of both proteins can still be detected after the 
integrity of the BBB is re-established. By using the vascular tracers FITC-albumin and Texas 
Red® cadaverine we could narrow down the time frame of increased BBB leakage to 
between 3 and 24 h after lesion induction. This also demonstrates that the BBB is closed to 




In addition, some extravasation of tracers was also observed 6 h after injection of ctrl-Ab and 
human complement, but represented only 48.8% (FITC-albumin) and 52.3% (Texas Red® 
cadaverine) of the extent of extravasation detected after injection of NMO-Ab (Figure 5 C, F). 
 
Figure 5: Restoration of the BBB within 24 h of focal intracerebral injection of NMO-Ab and human 
complement 
6 h after focal injection a prominent extravasation of FITC-albumin (A) and Texas Red® cadaverine (D) into the 
brain parenchyma was observed. No vascular leakage of either molecule was detected 24 h after stereotactic 
injection (B: FITC-albumin, E: Texas Red® cadaverine). Quantification of extravasation demonstrated that the 
BBB was permeable for FITC-albumin and Texas Red® cadaverine at 6 h. However, it was restored within 24 h 
after focal injection of Ab and human complement. Moreover, no extravasation of FITC-albumin was observed 
at 3 h and 3 d after lesion induction. At 6 h after stereotactic injection, some extravasation of both tracer 
molecules was also detected in animals injected with ctrl-Ab and human complement. However, the area of 
extravasation was substantially smaller in ctrl-Ab injected animals and covered around 50% of the area 
observed in NMO-Ab injected animals (FITC-albumin: 3 h: n=3, 6 h: n=8, 24 h: n= 9, 3d: n=4, C, Texas Red® 
cadaverine: n= 3, F). Kruskal-Wallis test followed by Dunn’s multiple comparison test *p<0.05, **p<0.01. 
Graphs are shown as mean ± SD. Scale bar 500 µm 
3.2 Co-culture of rat brain endothelial cells (RBEC) with astrocytes as an in-
vitro model of the BBB did not result in increased TEER values 
24 h after lesion induction the greatest extent of astrocyte loss was observed (Figure 3 G). 
However, no extravasation of i.v. injected exogenous tracer molecules was detected at that 
time point in vivo (Figure 5). Therefore, the direct influence of factors released by astrocytes 
on the transendothelial electrical resistance (TEER) of primary RBEC monolayers was 
investigated in vitro. TEER measurements are an important readout to assess the integrity of 




Therefore, the higher the resistance, the lower the permeability of the EC monolayer to 
sodium ions. 
17 d old Wistar rats were used for the isolation of primary RBEC. Isolated RBEC grew in a 
dense monolayer and had a spindle shaped morphology. Additionally, immunocytochemistry 
demonstrated the localization of the endothelial cell marker von Willebrand factor (vWF) in 
the Weibel-Palade bodies of RBEC (Figure 6 A). Furthermore, RBEC expressed the TJ 
molecules occludin, claudin-3 and -5 which were localized at the cell borders (Figure 6 A). 
The expression of TJ molecules implicates a preservation of the primary BBB phenotype. 
In order to investigate the influence of factors released by astrocytes on the TEER values of 
the RBEC monolayer, an indirect co-culture model was developed. A transwell system was 
used in which primary rat astrocytes were plated in the basolateral compartment and RBEC 
in the apical compartment (Figure 6B). Starting from day 3 after isolation TEER values were 
measured daily. The electrical resistance increased until day 6 after RBEC isolation. Starting 
from day 6 on, TEER values decreased. This was due to RBEC apoptosis and formation of 
holes in the monolayer as assessed by light microscopy. Co-culture of RBEC with astrocytes 
did not result in a significant change of electrical resistance compared to RBEC cultured 
alone at any time point investigated (Figure 6C). 
 
Figure 6: Co-culture of RBEC with astrocytes as an in vitro model of the BBB did not result in altered 
TEER values. 
Immunocytochemistry of endothelial marker molecules is depicted in A. Isolated primary RBEC stain positively 
for the endothelial cell marker vWF, which is stored in the Weibel-Palade bodies. Additionally they display the 
TJ molecules occludin, CLDN3 and CLDN5 located at the endothelial cell-cell contacts (A). Co-culture model of 
the BBB with primary rat astrocytes growing in the basolateral compartment, and RBEC plated in the apical 




measurement was performed from RBEC grown alone. Subsequently, inserts containing RBEC were transferred 
into wells with a confluent astrocyte monolayer (indicated by red arrow). However, co-culture of astrocytes did 
not affect TEER values of RBEC (pooled data of 3 independent experiments performed in triplicates, C). Data 
are shown as mean ± SD. Scale bar 40 µm. 
3.3 Platelet-derived growth factor receptor ß (PDGFRß) positive cells are in 
close proximity to brain vessels 6 h and 24 h after lesion induction 
It has been reported previously that pericytes play an important role for the development of 
the BBB and for its maintenance in the adult animal in vivo (Armulik et al., 2010; Bell et al., 
2010; Daneman et al., 2010b). They are - beside EC, the basal lamina and astrocytes - a 
further component of the BBB. Pericytes ensheath blood vessels and share a basement 
membrane with EC. CNS vessels have the highest density of pericyte coverage in the body 
(Shepro and Morel, 1993). In order to assess the presence of pericytes within astrocyte 
depleted lesions animals were stereotactically injected with NMO-Ab and human 
complement and sacrificed 6 h and 24 h later. Perilesional brain tissue was used as control. 
PDGFRß, a marker for pericytes, was used to investigate the presence of pericytes at the 
BBB. In addition, to visualize the blood vessels, the basal lamina was stained using an Ab 
against laminin γ1 (LAMγ1). Astrocyte depleted areas in NMO-Ab injected animals were 
visualized using anti-GFAP Ab. 
In perilesional tissue PDGFRß positive cells (green) line the brain vessels which are also 
surrounded by a LAMγ1 (red) positive basal lamina (Figure 7 A). After 6 h (Figure 7 B) and 
24 h (Figure 7 C) of NMO lesion induction, expression of PDGFRß on LAMγ1 positive vessels 
was not altered in astrocyte depleted areas compared to perilesional tissue. This indicates 





Figure 7: No loss of PDGFRß positive cells from the blood vessels in NMO-like lesions 6 h and 24 h 
after focal NMO-Ab injection 
PDGFRß positive cells (green) ensheath brain vessels marked by the basal lamina component LAMγ1 (red) in 
perilesional brain tissue (A). The staining pattern is not altered in astrocyte depleted lesions 6 h (B) and 24 h (C) 
after lesion induction. Scale bar 20 µm 
3.4 Characterization of tight junctions (TJ) in NMO-like lesions 
TJ are the major structure responsible for the low permeability of the BBB. They are located 
at the cell-cell contacts of adjacent EC and prevent the paracellular diffusion of blood-borne 
molecules into the CNS. Disruption of TJ morphology or loss of TJ proteins from the 
vasculature were implied in the loss of BBB integrity in neuroinflammatory diseases like 
multiple sclerosis (MS) or its model experimental autoimmune encephalomyelitis (EAE) 
(Argaw et al., 2009; Errede et al., 2012; Kirk et al., 2003; Plumb et al., 2002; Wolburg et al., 
2003). In focal NMO-like lesions a transient loss of the BBB integrity is observed. In order to 
investigate a correlation between a loss of TJ proteins and the breakdown of the BBB, the 
transmembrane TJ proteins occludin, claudin-3 and -5 were investigated on the 
immunohistochemical and mRNA levels. In addition, electron microscopy (EM) of blood 




3.4.1 Transient loss of occludin from TJ after lesion induction 
The transmembrane TJ proteins occludin, claudin-3 and -5 are highly expressed in the brain 
vasculature and disruption of their expression has been implied in the dysfunction of the 
BBB (Kirk et al., 2003; Liebner et al., 2000a; Plumb et al., 2002; Wolburg et al., 2003). In 
order to investigate whether the transient breakdown of the BBB observed during the 
development of focal NMO-like lesions correlates with a loss of TJ molecules from the brain 
vasculature, a time course study was performed. Animals were injected with NMO- or ctrl-
Ab together with human complement and sacrificed after 6 h, 10 h, 24 h, 3 d or 6 d. Since a 
certain loss of BBB integrity was also observed in animals injected with ctrl-Ab and human 
complement (Figure 4 and Figure 5) uninjected brain tissue from naïve rats was used as 
additional control. Immunofluorescent staining with Ab against occludin, claudin-3 and -5 
was used to investigate TJ proteins at the BBB. Double-labeling with the basal lamina 
component LAMγ1 was performed to visualize blood vessels. Immunohistochemistry for 
GFAP demarcated the astrocyte lesion border in NMO-Ab injected animals. The percentage 
of LAMγ1-positive blood vessels with vascular localization of the TJ proteins occludin, 
claudin-3 or -5 was determined for each animal. In NMO-Ab injected animals, blood vessels 
within areas of GFAP loss were evaluated, whereas in ctrl-Ab injected animals the 
corresponding area adjacent to the injection site, marked by Monastral blue, were assessed. 
In uninjected, naïve controls, sharply defined strands of occludin immunoreactivity (green) 
marking the paracellular cleft of adjacent EC within the LAMγ1-immunopositive basal 
membrane (red) were observed (Figure 8 A). Quantification of occludin positive vessels 
revealed occludin immunoreactivity in 93.3 ± 3.3% of the vessels in the brain of uninjected 
controls. However, loss of occludin immunoreactivity from TJ in LAMγ1 positive vessels was 
observed 10 h and 24 h after lesion induction (3.5 ± 2.2% (10 h) and 3.4 ± 3.4% (24 h) of 
vessels are immunopositive for occludin, Figure 8 A, D). 3 d after lesion induction a vascular 
localization of occludin within GFAP depleted areas was again observed in 68.5 ± 4.6% of the 
blood vessels (Figure 8 A, D), indicating occludin restoration at TJ. 6 d later, the localization 
of occludin at the TJ was restored and no difference in occludin immunoreactivity was 
detected compared to uninjected controls. Here, 94.6 ± 3.0% of the vessels stained 
positively for occludin which was similar to 93.3 ± 3.3% in naïve controls (Figure 8 D). A less 
pronounced reduction of occludin positive vessels was also observed in ctrl-Ab injected 
animals 10 h and 24 h after stereotactic injection (38.2 ± 15.2% and 31.9 ± 31.5% of vessels 




In contrast, no loss of claudin-3 and -5 immunoreactivity (green) from LAMγ1 positive 
vessels (red) was observed at any time point investigated (Figure 8 B, C, E, F). In both, 
uninjected controls and GFAP depleted lesions 10 h after lesion induction, sharply defined 
claudin-3 and -5 immunoreactivity marking the paracellular cleft of adjacent EC within the 
LAMγ1-immunopositive basal membrane was observed (Figure 8 B, C). Assessment of the 
percentage of claudin-3 and -5 positive vessels revealed no alterations of claudin-3 and -5 
immunoreactivity 6 h, 10 h, 24 h, 3 d or 6 d after lesion induction compared to ctrl-Ab 
injected animals and uninjected controls (Figure 8 E, F). Claudin-3 immunoreactivity was 
detected in 76.9 % ± 8.7 (24 h NMO-Ab) to 91.9 % ± 2.7 (3 d ctrl-Ab) of LAMγ1 positive 
vessels (Figure 8 E), and claudin-5 immunoreactivity was detected in 85.5 % ± 8.1 (10 h 
NMO-Ab) to 97.1 % ± 1.9 (6 d NMO-Ab) of LAMγ1 positive vessels (Figure 8 F). 
In summary, a transient loss of occludin starting from 6 h after lesion induction was 
observed. Localization of occludin at the TJ was partially recovered 3 d after lesion induction 
and back to control levels after 6 d. No loss of claudin-3 or -5 from the TJ was detected at 





Figure 8: Loss of occludin from the blood vessels was observed in focal NMO-like lesions 
Immunolabelling for occludin, claudin-3 and -5 (green) was performed to assess the localization of these TJ 
proteins in brain vessels (visualized with LAMγ1, a marker of the basal lamina, red) around the injection site. 
Immunoreactivity for occludin (A), claudin-3 (B) and -5 (C) was localized at the TJ between adjacent EC which 
formed sharply defined, continuous strands in uninjected, naïve controls. However, loss of occludin 
immunoreactivity was observed 10 h and 24 h after lesion induction in astrocyte depleted areas. Vascular 
occludin localization was recovered to 68.5 ± 4.6% within 3 d after focal injection of NMO-Ab and human 
complement (A). Quantification of occludin positive vessels confirms the transient loss of occludin 
immunoreactivity from the blood vessels in areas of GFAP loss. A less pronounced decrease of occludin-
immunopositive vessels was also observed in animals injected with ctrl-Ab together with human complement 




n=3, NMO-Ab/ctrl-Ab; 6h: n=4/0; 10h: n=3/3; 24h: n=3/2; 3d: n=3/3; 6d: n=3/3, D). In contrast, no loss of 
claudin-3 and -5 immunoreactivity was detected after lesion induction and sharply defined immunoreactivity 
for claudin-3 (B) and -5 (C) was observed at the TJ of LAMγ1 positive vessels at 10 h. Quantification of claudin-3 
positive vessels (45-218 vessels/animal evaluated; ctrl n=3, NMO-Ab/ctrl-Ab; 6h: n=4/0; 10h: n=2/3; 24h: 
n=3/2; 3d: n=2/2; 6d: n=3/3, E) and claudin-5 positive vessels (28-209 vessels/animal, ctrl n=3, NMO-Ab/ctrl-Ab; 
6h: n=4/0; 10h: n=3/3; 24h: n=3/2; 3d: n=3/2; 6d: n=3/3, F) confirms this observation. Kruskal-Wallis test 
followed by Dunn’s multiple comparison test *p<0.05. Data are shown as mean ± SD. Scale bar 50 µm. 
bv=blood vessels. 
3.4.2 No morphological alterations of TJ on the ultrastructural level 
A transient loss of occludin immunoreactivity from the TJ of LAMγ1 positive vessels was 
observed starting 6 h after lesion induction. Only about 3.5% of the blood vessels showed 
occludin immunoreactivity 10 h and 24 h after lesion induction. However, no loss of claudin-
3 and -5 immunoreactivity was detected (Figure 8). In order to investigate whether the 
selective loss of occludin immunoreactivity from the TJ of brain vessels results in 
morphological alterations on the ultrastructural level, i.e. separation of adjacent EC, EM was 
performed. Animals were stereotactically injected with NMO-Ab and human complement 
and sacrificed 6 h and 24 h after lesion induction. 
To ensure the presence of a fully developed astrocyte depleted lesion, the caudal part of the 
lesion was used for immunohistochemistry, while the rostral part was prepared for EM. 
GFAP-immunohistochemistry demonstrated the depletion of astrocytes. Using EM a close 
association between adjacent EC was observed in uninjected controls. No overt 
morphological TJ abnormalities or any separation of adjacent EC were detected 6 h and 24 h 
after lesion induction (Figure 9). 
 
Figure 9: Ultrastructure of TJ in cerebral blood vessels after lesion induction 
TJ were observed between adjacent EC in ultra-thin sections using EM. Injection of NMO-Ab and human 
complement did not result in overt morphological alterations of TJ complexes. Depicted images show 
representative TJ of brain blood vessels in uninjected controls and 6 h or 24 h after lesion induction. Arrows 




3.4.3 mRNA levels of occludin and claudin 5 are increased in NMO-like lesions 
In order to evaluate if changes in mRNA expression of TJ genes are induced during the 
development of NMO-like lesions a quantitative PCR study was performed. Animals were 
stereotactically injected with NMO- or ctrl-Ab together with human complement and 
perfused 10 h, 24 h, 3 d or 6 d after stereotactic injection. Uninjected brain tissue served as 
negative control. Subsequently, the tissue was cut into 10 µm thick sections using a cryostat, 
mounted on polyethylene naphthalate membranes and stained for GFAP using a rapid 
staining protocol to avoid RNA degradation. Brain areas with loss of astrocytes were isolated 
under the microscope from NMO-Ab injected animals using laser capture microdissection. In 
animals injected with ctrl-Ab and human complement the area around the injection site was 
dissected or the respective brain area in uninjected controls. Subsequently, TaqMan Gene 
Expression Assay for occludin, claudin-3 and -5 were performed. The house keeping gene 
gapdh served as control. CT values for expression of TJ genes were normalized to CT values of 
gapdh to calculate ∆CT values (CT TJ gene - CT gapdh). ∆∆CT values were calculated by 
subtraction of the ∆CT value of uninjected controls from ∆CT values obtained after lesion 
induction. 
10 h and 24 h after stereotactic injection of NMO- or ctrl-Ab together with human 
complement, mRNA expression of occludin and claudin-5 were increased compared to 
uninjected controls (∆∆CT values of NMO-/ctrl-Ab injected animals after 10 h: 
occludin=3.2/3.7, claudin-5=2.8/3.9; after 24 h: occludin=2.6/2.2, claudin-5=1.5/0.7). 3 d 
after stereotactic injection mRNA expression of occludin was similar to control levels while 
expression of claudin-5 was decreased (∆∆CT values of NMO-/ctrl-Ab injected animals: 
occludin=-0.3/ 0.2, claudin-5=-1.7/-1.0). After 6 d ∆∆CT values of -0.7/-0.4 (occludin) and -
0.1/-0.5 (claudin-5) were measured (Figure 10). No time dependent regulation of claudin-3 
mRNA expression was observed, however an increased mRNA expression was measured 
24 h after focal injection of NMO-Ab and human complement (∆∆CT = 2.6, Figure 10). In 
summary, occludin and claudin-5 mRNA expression was increased 10 h and 24 h after 
stereotactic injection. No difference in mRNA expression was observed between animals 






Figure 10: mRNA expression of occludin and claudin-5 were increased 10 h and 24 h after 
stereotactic injection 
Increased expression of occludin and claudin-5 mRNA was measured 10 h and 24 h after stereotactic injection 
of NMO- or ctrl-Ab compared to uninjected controls. After 3 d and 6 d mRNA expression of occludin and 
claudin-5 were decreased (claudin-5 after 3 d) or similar to uninjected controls. No time dependent regulation 
of claudin-3 was observed (number of animals measured at 10h/24h/3d/6d, occludin NMO: n=2/3/2/4, 
occludin ctrl: n=3/4/3/4, claudin-3 NMO: n=3/4/2/4, claudin-3-ctrl: n=4/3/3/4, claudin-5 NMO: n=2/3/2/4, 
claudin-5 ctrl: n=4/2/3/4). 
3.5 Infiltration of polymorphonuclear cells (PMN) correlates with FITC-
albumin extravasation 6 h after lesion induction 
The infiltration of immune cells into the brain parenchyma has been implied to mediate the 
breakdown of the BBB in diseases like NMO, multiple sclerosis or cerebral ischemia and their 
animal models (Bartholomaus et al., 2009; Carlson et al., 2008; Grossman et al., 1986; 
Morrissey et al., 1996; O'Riordan et al., 1996; Virapongse et al., 1986). Moreover, infiltration 
of immune cells into the brain has been described upon induction of focal NMO-like lesions 
24 h and 7 d after lesion induction (Wrzos et al., 2014). In order to investigate the sequence 
of infiltrating immune cells in NMO-like lesions, animals were stereotactically injected with 
NMO-Ab and human complement and subsequently sacrificed after 3 h, 6 h, 12h, 24 h, 3 d or 
7 d. To visualize immune cell subsets immunohistochemistry against ED1 (macrophages/ 
activated microglia) and CD3 (T cells) was performed. In addition, chloroacetate esterase 
enzyme histochemistry (CAE) was used to label PMN. 
To quantify infiltrating immune cell subsets, cells were enumerated using a light microscope 
with an ocular morphometric grid, and their density was calculated. 3 h after lesion 
induction no infiltration of immune cells was observed at the injection site (Figure 11 B). 
However, after 6 h infiltration of PMN with a density of 223 ± 101 PMN/mm² was detected 
which increased to 842 ± 71 after 12 h, and 801 ± 308 PMN/mm² after 24 h. Subsequently 
the PMN density again decreased to 314 ± 202 PMN/mm² 3 d after lesion induction. 7 d after 




Investigating the numbers of ED1 positive macrophages/activated microglia, only scattered 
ED1 positive cells were observed 6 h after lesion induction (2 ± 2 ED1 positive cells/mm²) 
which subsequently increased until the density peaked 24 h after lesion induction with 
453 ± 72 ED1 positive cells/mm². Numbers of macrophages/activated microglia subsequently 
decreased to 204 ± 34 ED1 positive cells/mm2 (3 d) and to 72 ± 57 ED1 positive cells/mm² 
(7 d after lesion induction, Figure 11 A, B). T cell numbers during the course of NMO-like 
lesion development remained low with a maximal density of 18 ± 16 CD3 positive T 
cells/mm² 7 d after lesion induction (Figure 11 A, B). 
The density of PMN/mm² was significantly higher compared to ED1 positive cells (*p<0.05) 
and CD3 positive T cells (***p<0.05) 6 h after focal injection of NMO-Ab and human 
complement (Figure 11 C). Therefore, a possible relationship between PMN and BBB 
permeability 6 h after lesion induction was investigated. The total number of parenchymal 
PMN around the injection site was determined and correlated with the measured area of 
FITC-albumin extravasation in serial sections. The number of PMN in the lesion correlated 
with the area of FITC-albumin extravasation (*p=0.0291, Pearson r=0.6271) potentially 






Figure 11: Strong infiltration of PMN correlated with extravasation of FITC-albumin 6 h after lesion 
induction 
Representative photographs depicting the infiltration of PMN (CAE, bright pink), macrophages/activated 
microglia (ED1, brown) and T cells (CD3, brown) 6 h, 24 h, 3 d and 7 d after lesion induction (A). Quantification 
of the infiltration of infiltrated immune cell subsets: no immune cell infiltration was observed in the brain 
parenchyma 3 h after lesion induction. 6 h after lesion induction infiltration of PMN was observed. PMN 
numbers increased with a maximal density between 12 h and 24 h after lesion induction and subsequently 
decreased. Infiltration of ED1 positive cells was observed starting at 6 h after lesion induction until they 
reached the highest density at 24 h after lesion induction. Subsequently the number of ED1 positive 
macrophages/activated microglia decreased. Only few CD3 positive T cells were detected (number of animals 
analyzed in CAE/ED1/CD3: 3 h n=4/4/4, 6 h: n=8/7/7, 12 h n= 2/2/2, 24 h n=7/6/7, 3 d: n=6/6/6, 7 d 6/6/5, B). 
PMN represented the highest density of all infiltrated immune cell subsets 6 h after lesion induction (n=8/7/7, 
C). The number of infiltrated PMN at this time point correlated with the area of FITC-albumin extravasation into 
the brain parenchyma (Pearson correlation for normally distributed samples *p=0.0291, Pearson r=0.6271, 
n=12, D). Monastral blue marks the injection site. Kruskal-Wallis test followed by Dunn’s multiple comparison 




3.6 Effect of PMN depletion on lesion development 
3.6.1 Depletion of PMN prevents astrocyte depletion, breakdown of the BBB 
and occludin loss 6 h after lesion induction 
The number of PMN in the lesion correlated with the area of FITC-albumin extravasation 6 h 
after lesion induction. To investigate whether PMN infiltration contributes to the breakdown 
of the BBB, PMN depletion studies were performed. In order to deplete PMN from the 
blood, animals were treated with 1 ml/kg body weight anti-PMN antiserum (AIA51140; 
Accurate Chemical and Scientific Corporation), at 18 h prior and directly after stereotactic 
injection of NMO- or ctrl-Ab together with human complement. Control rats received normal 
serum (normal rabbit serum; AIS403, Accurate Chemical and Scientific Corporation). To 
investigate the BBB integrity, FITC-albumin was injected 40 min before perfusion. Animals 
were sacrificed 6 h after lesion induction (Figure 12 A). CAE enzyme histochemistry was 
performed to visualize PMN. Immunohistochemistry for (i) FITC-albumin, (ii) astrocytes 
(GFAP), (ii) TJ proteins (occludin, claudin-3 and -5) and the basal lamina (LAMγ1) were 
performed to investigate (i) BBB integrity, (ii) astrocyte depletion and (iii) loss of TJ proteins 
from the vasculature after PMN depletion. 
To verify the depletion of PMN blood samples were collected before treatment and 6 h after 
lesion induction. Blood smear samples were analyzed by Giemsa stain. The number of PMN 
was counted among at least 300 cells on each slide and the number of PMN/100 white blood 
cells (WBCs) was determined. In blood samples obtained before treatment, 9.5 ± 3.0 
PMN/100 WBCs were detected. After treatment with normal serum 14.7 ± 5.2 PMN/100 
WBCs were observed in the blood samples. Anti-PMN antiserum treated animals, displayed a 
decrease of PMN numbers by 94% to 0.9 ± 0.5 PMN/100 WBCs. PMN numbers in normal 
serum treated rats were significantly higher compared to PMN numbers after treatment 
with anti-PMN serum (***p<0.001). Depletion of PMN was also confirmed in the brain 
parenchyma using CAE enzyme histochemistry. In rats treated with normal, but not anti-
PMN antiserum, infiltrated PMN were detected at the injection site after intracerebral 
injection of NMO-Ab and human complement (normal serum: 328 ± 136 PMN/mm², anti-
PMN serum: 0 ± 0 PMN/mm², ***p<0.001, Figure 12 B, C). Some infiltration of PMN was also 
observed after stereotactic injection of ctrl-Ab and human complement in rats treated with 
non-immune serum (129 ± 78 PMN/mm²), reaching 39.3% of the PMN numbers observed in 




Furthermore the permeability of the BBB after cerebral injection of ctrl-Ab/NMO-Ab 
together with human complement was assessed in PMN depleted and non-depleted 
animals. In non-PMN-depleted animals, a prominent extravasation of the exogenous tracer 
molecule FITC-albumin into the brain parenchyma was observed 6 h after lesion induction. A 
substantially smaller area of FITC-albumin extravasation was also detected after stereotactic 
injection of ctrl-Ab and human complement (area of FITC-albumin extravasation in mm²: 
NMO-Ab=0.9 ± 0.5; ctrl-Ab=0.5 ± 0.3, 58.8% Figure 12 E). Depletion of PMN markedly 
reduced the extravasation of FITC-albumin in both NMO- and ctrl-Ab injected animals (area 
of FITC-albumin extravasation in mm²: NMO-Ab=0.06 ± 0.06; ctrl-Ab=0.05 ± 0.1), which was 
significant compared to non-PMN depleted NMO-Ab injected animals (**p<0.01, Figure 12 
D, E). 
In addition, depletion of astrocytes was assessed by GFAP immunohistochemistry. 6 h after 
focal injection of NMO-Ab and human complement, well demarcated GFAP depleted lesions 
were observed (area of GFAP-loss 0.6 ± 0.4 mm²), whereas in ctrl-Ab injected animals no 
astrocyte loss was detected (area of GFAP-loss 0.0 ± 0.0 mm², *p<0.05). Surprisingly, 
depletion of PMN in rats completely inhibited astrocyte lesion formation 6 h after focal 
injection of NMO-Ab and human complement (area of GFAP-loss 0.0 ± 0.0 mm², ***p<0.001, 
Figure 12 F, G). 
Furthermore, the effect of PMN depletion on the localization of occludin, claudin-3 and -5 at 
the TJ in LAMγ1 positive blood vessels was investigated 6 h after intracerebral injection of 
NMO-Ab and human complement. The percentage of occludin positive vessel in uninjected 
brain tissue was 93.9 ± 3.3%. A significant reduction to 30.6 ± 20.2% occludin positive vessels 
was observed 6 h after lesion induction (**p<0.01). However, this reduction was not 
observed in PMN depleted animals (87.1 ± 1.9 % occludin positive vessels). The numbers of 
claudin-3 and -5 positive vessels were not altered 6 h after NMO-Ab injection with and 
without PMN depletion compared to untreated controls. The percentages of LAMγ1 positive 
vessels with claudin-3 immunoreactivity were: uninjected brain tissue=90.4 ± 3.1%; NMO-
Ab=91.5 ± 0.5%; and NMO-Ab after PMN depletion=91.1 ± 2.6%. The percentages of LAMγ1 
positive vessels with claudin-5 immunoreactivity were: uninjected brain tissue=94.2 ± 2.9%; 
NMO-Ab=91.5 ± 3.5%; and NMO-Ab after PMN depletion=92.1 ± 2.7%. (Figure 12 H). 
These data indicate a crucial role for PMN in the development of NMO-like lesions, since 
depletion of PMN prevents breakdown of the BBB, loss of occludin from TJ and loss of 




human complement alone resulted in the infiltration of PMN (Figure 12) a subsequent 
breakdown of the BBB (Figure 4, Figure 5 and Figure 12) and loss of occludin from the TJ 
(Figure 8), however substantially milder than in NMO-Ab injected rats. This emphasizes the 











Next page  
Figure 12: Depletion of PMN inhibited astrocyte lesion formation, breakdown of the BBB and loss 
of occludin form the TJ 6 h after lesion induction 
Experimental setup to assess the influence of PMN in the development of focal NMO-like lesions is depicted in 
(A). Focal injection of NMO-Ab or ctrl-Ab together with human complement results in the infiltration of CAE 
positive PMN (pink). Animals treated with normal rabbit serum showed 2.5 times more infiltrated PMN at the 
NMO-Ab injected hemisphere than the ctrl-Ab injected hemisphere. Depletion of PMN from the blood is 
reflected by the absence of PMN infiltration in the cortex 6 h after focal injection of NMO- or ctrl-Ab together 
with human complement (B, quantification: C). Furthermore, depletion of PMN decreased the permeability of 
the BBB to FITC-albumin 6 h after focal injection of NMO- or ctrl-Ab together with human complement (D, 
quantification: E). Loss of GFAP immunoreactivity was observed 6 h after focal injection of NMO-Ab, but not 
ctrl-Ab together with human complement. Loss of GFAP positive cells was inhibited by treatment with anti-
PMN serum (F, quantification: G). C, E, G: n=6, pooled data of 2 independent experiments. Furthermore, the 
localization of occludin, claudin-3 and-5 at the TJ was investigated in PMN depleted and non-depleted animals 
6 h after NMO-Ab injection. Injection of NMO-Ab together with human complement resulted in selective loss of 
occludin immunoreactivity from the TJ in normal serum injected animals. PMN-depletion inhibited loss of 
occludin immunoreactivity from blood vessels and was not altered compared to uninjected control brain. No 
changes in the percentage of claudin-3 and -5 positive blood vessels were observed 6 h after lesion induction in 
PMN-depleted or non-depleted animals compared to uninjected control brain (ctrl n=3, 6 h NMO-Ab anti-PMN 
and ctrl: n=4, H). Kruskal-Wallis test followed by Dunn’s multiple comparison test *p<0.05, **p<0.01, 
***p<0.001. Data are shown as mean ± SD. F: Dotted lines indicate area of GFAP loss. Scale bars: 50 µm (B) and 








3.6.2 Treatment with anti-PMN antiserum decreases immune cell numbers in 
the blood 
In order to investigate if anti-PMN antiserum selectively depletes PMN without affecting the 
numbers of other immune cell subsets flow cytometry was performed. Rats were treated 
with either anti-PMN antiserum (AIA51140; Accurate Chemical and Scientific Corporation) or 
normal serum (normal rabbit serum; AIS403, Accurate Chemical and Scientific Corporation) 
as described above (section 3.6.1). Blood was collected 6 h after the second serum 
treatment and processed for flow cytometry by Michael Haberl (Department of 
Neuroimmunology, Institute for Multiple Sclerosis Research, Göttingen). FACS staining was 
performed for T cells (CD4 and CD8), myeloid cells (CD11b), B cells (CD45RA) and PMN (RP-
1). 
The numbers of PMN were strongly decreased in rats treated with anti-PMN antiserum and 
represented 0.8% of the PMN numbers detected in normal serum treated rats. However, a 
reduction of immune cells/ml to 5.5 - 8.1% of the cell numbers measured in normal serum 
treated rats was also observed in all leukocyte subsets investigated (Figure 13). In detail, 
PMN were reduced from 1.68 ± 1.1 x 106 cells/ml in normal serum treated animals to 0.01 ± 
0.01 x 106 cells/ml in anti-PMN antiserum treated animals. Furthermore, decreased numbers 
of T cell were detected: CD4 positive T cells were reduced to 6.5% and CD8 positive T cells to 
5.5% in anti-PMN antiserum treated animals (normal serum: 3.2 ± 1.5 x 105 CD4 + T cells/ml 
and 2.1 ± 0.2 x 105 CD8 + T cells/ml; anti-PMN: 0.21 x 105 ± 0.13 x 105 CD4 + T cells/ml and 
0.12 x 105 ± 0.03 x 105 CD8 + T cells/ml). B cell numbers were decreased from 1.10 ± 0.55 x 
105 B cells/ml in normal serum treated animals to 0.09 ± 0.08 x 105 B cells/ml in anti-PMN 
antiserum treated rats, which represents a reduction to 8.1%. In addition, CD11b positive 
myeloid cells decreased to 6.6% after anti-PMN antiserum treatment (normal serum: 7.03 ± 






Figure 13: Treatment of animals with anti-PMN antiserum resulted in a strong decrease of PMN 
numbers but also a non-selective reduction of leukocytes compared to normal serum treated 
animals 
Treatment of rats with anti-PMN antiserum strongly decreased the numbers of RP-1 positive PMN to 0.8% in 
relation to the PMN number detected after treatment with normal serum. However, the depletion of PMN with 
anti-PMN antiserum was not selective. In addition, reduced numbers of CD4 and CD8 positive T cells, CD45R 
positive B cells and CD11b positive myeloid cells were observed after anti-PMN antiserum treatment. n in each 
group=3 
3.7 Inhibition of complement component C5a receptor (C5aR) significantly 
reduces astrocyte lesion size 6 h after lesion induction 
The development of focal NMO-like lesions is complement-dependent. After injection of 
NMO-Ab and human complement, lesion development is triggered by the binding of the 
NMO-Ab to AQP4 on astrocytes and the subsequent activation of the complement cascade 
which results in the lysis of astrocytes (Wrzos et al., 2014). During the activation of the 
complement cascade, C5 convertase becomes activated and cleaves the inactive C5 into the 
active component C5b and the anaphylatoxin C5a. Its receptor C5aR is highly expressed on 
PMN. C5a acts as a potent PMN chemoattractant, but is also important for PMN activation. 
In order to inhibit C5aR mediated signaling the small molecule C5aR antagonist PMX-53 was 
used. Rats were focally injected with NMO-Ab together with human complement and were 
i.v. injected with 1 mg/kg body weight PMX-53 or vehicle 3 h later. Animals were sacrificed 
6 h after lesion induction (Figure 14 A). For assessment of BBB integrity FITC-albumin was i.v. 
injected 40 min before perfusion. Immunohistochemistry was used to investigate astrocyte 
lesion size (GFAP and AQP4) and BBB permeability (FITC-albumin and fibrinogen). 




Focal injection of NMO-Ab and human complement results in the formation of astrocyte 
depleted lesions with sizes of 0.4 ± 0.2 mm² (AQP4) and 0.4 ± 0.1 mm² (GFAP) in vehicle 
treated animals. Systemic treatment with the C5aR antagonist PMX-53 significantly reduced 
the size of astrocyte depleted lesions (AQP4: 0.2 ± 0.2 mm², *p=0.0291 and GFAP: 0.2 ± 0.2 
mm², **p=0.0039, Figure 14 B). The infiltration of PMN into the brain parenchyma 6 h after 
lesion induction, however, was not significantly altered between vehicle and PMX-53 treated 
animals (vehicle: 538 ± 262 PMN/mm², PMX-53: 329 ± 231 PMN/mm², Figure 14 C). 
Furthermore, no difference in BBB permeability was observed. The area of FITC-albumin 
extravasation was 1.1 ± 0.6 mm² in vehicle and 1.0 ± 0.6 in PMX-53 treated animals (Figure 
14 D). Similar values were obtained for the area of fibrinogen extravasation (vehicle: 1.3 ± 
0.8 mm², PMX-53: 1.1 ± 0.6 mm², Figure 14 E). 
 
Figure 14: Decreased astrocyte loss after systemic treatment with the C5aR antagonist PMX-53 6 h 
after lesion induction 
Schematic illustration of the experimental setup to investigate the influence of the C5aR antagonist PMX-53 on 
the development of NMO-like lesions is depicted in (A). Treatment of rats with the C5aR antagonist PMX-53 
significantly decreased the areas with loss of GFAP and AQP4 immunoreactivity compared to vehicle treated 
animals (B). However, infiltration of PMN was not altered in PMX-53 compared to vehicle treated animals (C). 
Additionally, no effect of PMX-53 treatment on the preservation of BBB integrity was observed, which was 
assessed by the measurement of FITC-albumin (D) and fibrinogen extravasation (E). Vehicle treated animals 
n=8, PMX-53 treated animals n=10, pooled data of 2 independent experiments. Unpaired t-test with Welch’s 




3.8 Investigation of PMN granule proteases in the regulation of BBB 
permeability 
PMN interactions with the endothelium under inflammatory conditions can result in the 
dysfunction of the BBB and an increased permeability. Several secreted PMN products have 
been implied to increase the endothelial permeability, like the proteases cathepsin G, 
neutrophil elastase (NE) and matrix metalloproteinase 9 (MMP9) (Chen et al., 2009; 
Hermant et al., 2003; Suzuki et al., 1994). In order to assess the direct effect of these 
proteases on brain endothelial cells, in vitro experiments were performed. Furthermore, the 
localization of MMP9 in infiltrating PMN and the effect of NE inhibition were investigated in 
vivo. 
3.8.1 Treatment of RBEC with MMP9 decreases electrical resistance in vitro 
PMN granules contain proteases like cathepsin G, NE and MMP9 which are released upon 
PMN activation. In order to investigate a direct effect of these proteases on the TEER values 
of confluent RBEC monolayers, cathepsin G (0.06 U/ml), NE (6 µg/ml) or MMP9 (0.5 µg/ml) 
were added to the apical compartment of a transwell system containing RBEC (Figure 15 A). 
TEER was measured before treatment and after 60 min and 120 min. Untreated RBEC 
monolayers were used as controls. To exclude a direct cytotoxic effect of the proteases on 
RBEC, the lactate dehydrogenase (LDH) based CytoTox-ONE™ Homogeneous Membrane 
Integrity Assay was applied. To assess the localization of occludin and claudin-5 in RBEC after 
treatment with MMP9 immunocytochemistry was performed. 
Before treatment TEER values of 41 ± 2 Ω*cm² across RBEC monolayers were measured. 
Treatment of RBEC with neither cathepsin G nor NE decreased TEER. In detail, in cathepsin G 
treated cells TEER values of 37 Ω*cm² (60 min) and 36 Ω*cm² (120 min) were determined. 
Treatment with NE resulted in an electrical resistance of 39 Ω*cm² (60 min) and 35 Ω*cm² 
(120 min). Both did not differ to untreated controls (60 min: 38 Ω*cm² and 120 min: 38 
Ω*cm²). Compared to untreated controls, however, MMP9 treatment of RBEC strongly 
decreased TEER values at both time points (23.4 Ω*cm² (60 min) and 19.5 Ω*cm² (120 min), 
Figure 15 B). To assess a possible cytotoxic effect of cathepsin G, NE or MMP9 treatment on 
RBEC, the release of LDH by damaged cells as a biomarker for cellular cytotoxicity and 
cytolysis was measured after 120 min of treatment. Compared to untreated controls no 
increase in LDH levels/cytotoxicity was observed after treatment with cathepsin G, NE or 
MMP9, confirming that a non-cytotoxic protease concentration was used for the transwell 




occludin or claudin-5 from the TJ at the endothelial cell contacts, immunocytochemistry was 
performed. In controls, occludin and claudin-5 immunocytochemistry was localized at the TJ 
between adjacent RBEC forming defined strands. No difference in staining pattern was 
observed after 120 min of incubation with MMP9 (Figure 15 D). 
 
Figure 15: Treatment of RBEC with MMP9, but not NE or cathepsin G, reduced TEER in vitro 
To investigate the effect of neutrophil proteases on BBB permeability, RBEC were incubated with cathepsin G, 
NE or MMP9 in vitro using a transwell system (A). Treatment of RBEC with MMP9 for 60 min and 120 min 
decreased TEER values while treatment with NE or cathepsin G did not alter TEER compared to untreated 
controls (B). To exclude a direct cytotoxic effect of MMP9, cathepsin G and NE on the RBEC, a LDH based assay 
for cytotoxicity was performed and the release of LDH by damaged cells as a biomarker for cellular cytotoxicity 
was measured. LDH release of the positive (pos) ctrl (RBEC treated with lysis buffer) was set to 100 % 
cytotoxicity. Compared to untreated (neg) ctrl no increase in LDH levels/cytotoxicity was detected in RBEC 
treated with MMP9 (0.5 µg/ml), cathepsin G (0.06 U/ml) or NE (6 µg/ml). (C). Immunocytochemistry for 
occludin and claudin-5 demonstrated localization of both TJ proteins between adjacent cells in untreated 
controls. No difference of occludin and claudin-5 immunoreactivity was observed after treatment with MMP9 
(D). Scale bar 50 µm 
3.8.2 MMP9 positive PMN are abundant in NMO-like lesions 6 h after lesion 
induction 
In order to investigate MMP9 expression in infiltrating PMN after lesion induction, a time 
course study was performed. Animals were focally injected with NMO-Ab and human 
complement and subsequently sacrificed 6 h, 12 h, 24 h and 3 d after lesion induction. 
Immunohistochemistry for MMP9 was performed. PMN were identified based on their 
multi-lobed nuclear morphology in Mayer’s hemalum counterstain. The total number of 
PMN was determined as well as the number of PMN with cellular MMP9 immunoreactivity 




6 h after lesion induction, in 19.3 ± 10.9% of PMN MMP9 immunoreactivity was observed 
which was localized within the cells in a granular pattern (Figure 16 A, arrowheads; C). 
Subsequently, a reduction of PMN with intracellular MMP9 immunoreactivity was detected. 
12 h after lesion induction 10.4 ± 8.7% of PMN were MMP9 positive which was reduced 
further to 1.7 ± 1.4% 24 h after lesion induction (Figure 16 B, C). No MMP9 positive cells 
were observed 3 d after lesion induction (Figure 16 C). 
 
Figure 16: Intracellular MMP9 expression was detected in infiltrating PMN 6 h and 12 h after lesion 
induction 
Numerous vascular and extravasating PMN displayed granular intracellular staining for MMP9 6 h after lesion 
induction (arrowheads, A). Rare MMP9 positive PMN were detected 24 h after lesion induction (B). 
Quantification of MMP9 positive PMN in the lesions displayed a continuous decrease of MMP9 
immunoreactivity within PMN. No MMP9 positive cells were observed 3 d after lesion induction (6 h n= 4, 12 h 
n= 2, 24 h n = 4, 3 d n = 3, C). Data are shown as mean ± SD. Scale bar 20 µm 
3.8.3 Inhibition of NE reduces astrocyte lesion size and PMN infiltration 6 h 
after lesion induction 
NE did not show a direct effect on TEER values of RBEC in vitro (Figure 15). However, in vitro 
and in vivo data indicate that NE cleaves the intercellular adhesion molecule 1 (ICAM-1) and 
thereby may play a role in PMN extravasation in vivo (Champagne et al., 1998; Kaynar et al., 
2008). To investigate the role of NE in the development of focal NMO-like lesions, the 
competitive NE inhibitor Sivelestat was used. Rats were intraperitoneal (i.p.) injected with 
50 mg/kg body weight Sivelestat or vehicle 3 h after focal injection of NMO-Ab and human 
complement. Subsequently, animals were sacrificed 6 h after lesion induction (Figure 17 A). 
For evaluation of the BBB integrity FITC-albumin was injected i.v. 40 min before perfusion. 
Immunohistochemistry was used to investigate astrocyte loss (GFAP and AQP4) and FITC-
albumin extravasation. Furthermore, CAE enzyme histochemistry was performed to visualize 
PMN. 
In vehicle treated animals astrocyte depleted lesions developed 6 h after lesion induction 
(AQP4: 0.3 ± 0.2 mm², GFAP: 0.3 ± 0.2 mm²). Treatment with the NE inhibitor Sivelestat 




0.1 ± 0.1 mm², *p=0.0415, Figure 17 B). Furthermore, the density of infiltrated PMN in the 
brain parenchyma was significantly decreased in Sivelestat treated animals compared to 
vehicle treated controls (vehicle: 603 ± 376 PMN/mm², Sivelestat: 256 ± 154 PMN/mm², 
*p=0.0387, Figure 17 C). However, no difference in FITC-albumin extravasation was observed 
between vehicle and Sivelestat treated animals (vehicle: 1.0 ± 0.6 mm², Sivelestat: 0.9 ± 0.6 
mm², Figure 17 D). 
 
Figure 17: Inhibition of NE using Sivelestat resulted in a significant reduction of astrocyte lesion size 
and PMN infiltration 6 h after lesion induction 
Illustration of the experimental setup to assess the influence of NE inhibition using Sivelestat in vivo (A). 
Treatment of animals with 50 mg/kg Sivelestat resulted in a significant reduction in the size of astrocyte 
depleted lesion compared to vehicle treated animals measured in AQP4 and GFAP immunohistochemistry (B). 
In addition, treatment with Sivelestat significantly decreased infiltration of PMN (C). Compared to vehicle 
treated animals no alterations in BBB permeability were detected after treatment with Sivelestat (D). Unpaired 
t-test with Welch’s correction, *p<0.05, n.s. = not significant. B, C: n=8; D: n=6, pooled data of two independent 
experiments. Data are shown as mean ± SD. 
3.9 PMNs are a component of the inflammatory infiltrate in early human NMO 
lesions 
In focal NMO-like lesions PMN play a crucial role in the regulation of BBB permeability and 
lesion development. Therefore, the immune cell infiltrate of early human NMO lesions was 
investigated. Early active human NMO lesions were characterized by focal loss of AQP4 and 
GFAP immunoreactivity, focal loss of Luxol fast blue (LFB) positive myelin sheets and relative 




AQP4 seropositive patients with confirmed NMO or NMO spectrum disorder were assessed. 
To visualize immune cell subsets immunohistochemistry against MRP14 (recently invaded 
monocytes/macrophages and PMN), KIM1P (macrophages/activated microglia) and CD3 (T 
cells) was performed. Infiltrating PMN numbers were evaluated in hematoxylin and eosin 
(HE) staining based on their multi-lobed nuclear morphology. 
A density of 132 ± 89 PMN/mm² (Figure 18 A, E, F (red dots)) and 465 ± 291 MRP14 positive 
cells/mm² (Figure 18 B, F (red dots)) was detected in biopsy tissue. These numbers were 
lower in autopsy tissue with a density of 2 ± 2 PMN/mm² (Figure 18 F (black dots)) and 45 ± 
63 MRP14 positive cells/mm² (Figure 18 F (black dots)). This difference might be due to the 
disease phase the tissue was collected. Although we investigated autopsy material with 
active, inflammatory NMO lesions, it is likely that these lesions reflect a more advanced 
(subacute) stage of NMO-lesion development, also considering the fact that most diagnostic 
biopsies are taken during acute disease phases. Furthermore, CD3 positive infiltrated T cells 
(95 ± 97 cells/mm², Figure 18 D, F) and abundant numbers of KiM1P positive 
macrophages/activated microglia (1195 ± 241 cells/mm², Figure 18 C, F) were observed in 







Figure 18: In the inflammatory infiltrate of early human NMO lesions PMN, monocytes, 
macrophages/activated microglia and T cells were observed 
Inflammatory infiltrates were observed in early active NMO lesions. These infiltrates were characterized by 
PMN (HE staining, A and higher magnification: E. Infiltrated PMN are indicated by arrows. The asterisk marks 
the lumen of a blood vessel from which PMN extravasate). In addition, PMN and early infiltrating monocytes 
were visualized by MRP14 immunohistochemistry (B). Furthermore, early human NMO lesions were 
characterized by abundant KiM1P positive macrophages/activated microglia (C) and CD3 positive T cells 
(arrows, D). Quantification of immune cells is depicted in (F). F: red: biopsies (n=5); black: autopsies (n=2). Cell 
numbers were evaluated using the following staining methods: PMN: HE; early monocytes/PMN: MRP14; 





Neuromyelitis optica (NMO) is a demyelinating disease in which astrocytes are the major 
target. Indeed, about 70% of NMO patients were found to be seropositive for antibodies 
(Ab) against aquaporin4 (AQP4) (Jarius et al., 2012b; Lennon et al., 2005; Lennon et al., 2004; 
Mealy et al., 2012; Waters et al., 2012) a water channel which is highly expressed on 
astrocytic endfeet in the central nervous system. Binding of this antibody to AQP4 on the 
astrocyte surface results in extensive complement and cell mediated astrocyte depletion 
during the acute phase of NMO lesion development. Astrocytes form, together with 
endothelial cells, pericytes and the basal lamina, the blood-brain barrier (BBB). Indeed, NMO 
patients manifest with a severe BBB disruption, as evidenced by multiple gadolinium 
enhanced lesions on magnetic resonance imaging (MRI) (de Seze et al., 2002; Ito et al., 2009; 
Kim et al., 2015; Wingerchuk et al., 1999). Furthermore, it was demonstrated that the extent 
of BBB permeability (measured by cerebrospinal fluid (CSF)/serum albumin ratios) correlated 
with the clinical disability (Tomizawa et al., 2012). Since the close interaction between 
different components of the BBB is necessary for maintaining its integrity, we hypothesized 
that the loss of astrocytes from the BBB in NMO lesions contributes to the severe BBB 
dysregulation that is observed in NMO patients. Therefore, the aims of this project were to 
characterize the breakdown of the BBB in an animal model of NMO in detail and to 
investigate its underlying mechanisms. In particular we were interested to examine whether 
there is (i) a correlation between BBB breakdown and astrocyte loss, (ii) a correlation 
between BBB breakdown and the disruption of tight junctions (TJ) at the BBB and (iii) a 
possible function of immune cells in the induction of BBB permeability. 
In the present study we showed, that (i) onset of the development of astrocyte depleted 
lesions correlated with the time point of BBB breakdown in vivo. However, the BBB integrity 
was restored before astrocytes repopulated the lesion as observed using vascular tracers. 
Additionally co-culture of rat brain endothelial cells (RBEC) with astrocytes did not increase 
transendothelial electrical resistance (TEER) in vitro. No loss of pericytes from astrocyte 
depleted lesions was observed. 
Furthermore, this work demonstrated that (ii) the TJ molecule occludin is selectively lost 
from the TJ in astrocyte depleted lesions but also reappears before astrocytes repopulate. 
Surprisingly, the BBB integrity to vascular tracer molecules was re-established before 
occludin immunoreactivity was again localized at the TJ. However, claudin-3 and -5 




morphological alterations of the TJ at endothelial contacts were detected on ultrastructural 
level using electron microscopy (EM). An increased mRNA expression of the TJ molecules 
occludin and claudin-5 was measured 10 h and 24 h after lesion induction. 
Additionally, the present work aimed to investigate the role of immune cells in the 
development of focal NMO-like lesions (iii). 6 h after lesion induction polymorphonuclear 
cells (PMN) were the most abundant infiltrating immune cell subset and the number of PMN 
in the lesions correlated with the area of fluorescein isothiocyanate (FITC)-albumin 
extravasation. Depletion of PMN abrogated lesion development and prevented breakdown 
of the BBB. Furthermore, inhibition of the complement component C5a receptor (C5aR), 
which is important for PMN attraction and activation, reduced the area of astrocyte loss. 
Finally, it was demonstrated that proteases released from PMN granules upon activation 
were involved in the regulation of BBB permeability and astrocyte lesion formation. Matrix 
metalloproteinase 9 (MMP9) was shown to decrease TEER values of RBEC in vitro and was 
detected in infiltrating PMN 6 h and 12 h after lesion induction in vivo. Furthermore, 
inhibition of neutrophil elastase (NE) reduced astrocyte lesion size and PMN infiltration in 
vivo. 
In summary we could show that PMN play a crucial role in the development of NMO-like 
lesions and mediate the breakdown of the BBB. The disruption of the BBB allows 
complement components to gain access to the brain parenchyma and results in the 
recruitment of additional immune cells. Both factors contribute to astrocyte loss in NMO-like 
lesions. 
4.1 Rapid restoration of the BBB in the focal NMO model, independent of loss of 
astrocytes and occludin 
To investigate the BBB in NMO, we utilized a focal NMO model in Lewis rats which is based 
on injection of a recombinant human NMO-Ab, directed against AQP4, together with human 
complement into the motorcortex. Intracerebral injection results in NMO-like lesions which 
are characterized by complement mediated astrocyte lysis followed by a rapid loss of 
oligodendrocytes and a delayed demyelination (Wrzos et al., 2014). Additionally, immune 
cell infiltration was observed, consisting mainly of PMN and macrophages. Astrocyte, 
oligodendrocyte and myelin loss, as well as PMN infiltration and abundant numbers of 
macrophages in the lesions are characteristics of early human NMO lesions (Cloys and 




1 and Figure 18. Therefore, focal NMO-like lesions resemble early human NMO lesions in 
many aspects, especially since the NMO-Ab utilized is derived from a plasma cell of an NMO 
patient (Bennett et al., 2009). Furthermore, the usage of a recombinant human NMO-Ab for 
lesion induction - in contrast to patient sera - ensures the induction of reproducible NMO-
like lesions which present a valuable tool to study astrocyte lesion development, also with 
regard to the regulation of the BBB permeability in the absence of astrocytes. 
The BBB restricts the movements of serum molecules from the blood into the brain and 
thereby maintains the unique central nervous system (CNS) environment which enables 
neuronal function. It is well established that “typical” BBB properties of endothelial cells 
(EC), such as the development of tight interendothelial junctions or the polarized expression 
of transporter systems, depend on cellular and structural components of the CNS. This 
includes astrocytes, pericytes and the basal lamina, and in the broader term of the 
neurovascular unit (NVU) additionally microglia and neurons (Abbott et al., 2006). The 
restriction of the transendothelial flux of sodium ions across the endothelium is a feature of 
the BBB that is mainly dependent of the development of tight interendothelial junctions, and 
can be determined by the measurement of the electrical resistance. TEER values of about 
1800 Ω*cm² were measured in situ in the rat CNS, representing a tight barrier (Butt et al., 
1990). However, once isolated, the TEER values decrease to 50-150 Ω*cm² in monolayers of 
rat brain EC (e.g. de Vries et al., 1996; Demeuse et al., 2002; Perriere et al., 2007). Co-culture 
of brain endothelial monolayers with astrocytes and/or pericytes was shown to increase the 
TEER values, to reduce permeability and to result in an enhanced expression of TJ proteins 
(Demeuse et al., 2002; Nakagawa et al., 2009; Nakagawa et al., 2007; Perriere et al., 2007). 
In order to identify a possible temporal relationship between astrocyte loss and the 
disruption of the BBB in focal NMO-like lesions a detailed time course study was performed. 
We detected dying glial fibrillary acidic protein (GFAP) positive astrocytes 3 h after focal 
injection of NMO-Ab and human complement. 6 h after lesion induction well-demarcated 
areas of GFAP loss were observed (Figure 3). Subsequently, loss of GFAP immunoreactivity 
expanded until lesions developed the maximal extent between 24 h and 3 d. Loss of 
astrocytes was also confirmed by immunohistochemistry against the astrocytic markers 
AQP4 (Figure 3), S100 calcium-binding protein ß (S100ß) and excitatory amino-acid 
transporter 2 (EAAT2) (Wrzos et al., 2014). One week after lesion induction 91.1% of the 
formerly astrocytes depleted area was repopulated by GFAP positive astrocytes (Figure 3). 




unspecific control (ctrl)-Ab and human complement (Figure 3). Additionally, previous work of 
our group shows that intracerebral injection of NMO-Ab together with heat-inactivated 
human serum does not induce astrocyte loss (Wrzos et al., 2014). Concurrent with the 
development of well-demarcated astrocyte depleted lesions, a transient disruption of the 
BBB to the endogenous serum proteins immunoglobulin G (IgG) (150 kDa) and fibrinogen 
(340 kDa, Figure 4) and the vascular tracer molecules (FITC)-albumin (70 kDa) and Texas 
Red® cadaverine (0.69 kDa, Figure 5) was detected 6 h after lesion induction. Surprisingly, 
24 h after lesion induction the BBB integrity was restored as observed for the vascular 
tracers FITC-albumin and Texas Red® cadaverine although the highest extent of astrocyte 
loss was measured at that time point (Figure 1 and Figure 5). 
Although an improvement of the BBB phenotype of isolated brain EC has been described 
when co-cultured with astrocytes, only few studies are published that directly investigate 
the loss of astrocytes and its effect on the BBB integrity in the adult brain in vivo. Early 
transplantation studies suggest that astrocyte presence alone does not induce a BBB 
phenotype in vessels. When fetal CNS tissue was transplanted into cerebral ventricles and 
subsequently was penetrated by choroidal vessels, these vessels were permeable for tracer 
molecules although ensheated by astrocytes (Krum and Rosenstein, 1989; Rosenstein, 1987). 
To the contrary, it was shown that transplantation of cultured astrocytes but not fibroblasts 
into the anterior eye chamber of rats resulted in protein impermeable vessels which 
vascularized the graft originating from the iris (Janzer and Raff, 1987). However, the iris 
microvasculature is characterized by an ocular-brain barrier and subsequent studies showed 
the astrocyte graft to be poorly vascularized in contrast to the fibroblast graft in which 
additionally a significant inflammatory response was observed (Holash et al., 1993). Later, 
using 3-chloropropanediol in rats to selectively deplete astrocytes in a toxic model, it was 
demonstrated that astrocyte loss precedes the breakdown of the BBB to FITC-labeled 
dextran. However, similar to the results obtained in our experiments, the integrity of the 
BBB to tracer molecules > 10 kDa was restored in the absence of astrocytes (Willis et al., 
2004). This restoration of the BBB integrity was later attributed to the continued expression 
of adherens junction (AJ) molecules, a remodeling of the extracellular matrix and an 
infiltration of macrophages (Willis et al., 2013). In another toxic model using the glial toxin 
N-aminonicotinamine, Krum and colleague investigated the effect of astrocyte depletion on 
the endothelial BBB phenotype in a series of studies. They demonstrated that depletion of 
astrocytes in the brain did not result in a breakdown of the BBB to horseradish peroxidase or 




N-aminonicotinamine did not result in astrocyte death in the brain but in the spinal cord. 
Here, extravasation of horseradish peroxidase was observed from some, but not all 
astrocyte depleted vessels (Krum, 1994). In addition the expression of some microvascular 
markers (e.g. the glucose transporter 1 (Glut1)) stayed intact in the absence of astrocytes 
(Krum, 1994, 1996). In a genetic approach using mice expressing the herpes simplex virus 
thymidine kinase (HSV-TK) under the GFAP promoter, it was shown that ganciclovir 
mediated depletion of reactive, GFAP expressing astrocytes after a forebrain stab injury 
resulted in a prolonged opening of the BBB. In addition an increase and prolonged duration 
of leukocyte infiltration (including PMN, macrophages, monocytes and lymphocytes) was 
observed. However, it was not investigated whether the depletion of astrocytes or the 
increase in inflammatory cell infiltration were causing the prolonged disruption of BBB 
integrity (Bush et al., 1999). 
Therefore, the direct effect of the loss of astrocytes on the maintenance of the BBB in the 
adult brain is not yet completely understood. In addition it was shown that astrocytic 
activation, e.g. during neuroinflammation, can lead to the release of signaling molecules by 
astrocytes which modulate BBB permeability and the expression of cell adhesion molecules 
on the endothelial surface. This was demonstrated e.g. for the release of sonic hedgehog 
(Shh) (Alvarez et al., 2011), vascular endothelial growth factor A (VEGF-A) (Argaw et al., 
2009) and retinoic acid (Mizee et al., 2014). Our observation that astrocyte loss outlasts the 
loss of BBB integrity might be partially explained by the fact that in focal NMO-like lesions 
only a transient loss of astrocytes in a relatively small (about 1 mm² in diameter) and 
restricted area of the CNS is observed. To further investigate the influence of factors 
released by primary astrocytes on TEER values of RBEC, we established an in vitro model of 
the BBB in which both cell types were co-cultured in separate compartments of a transwell 
system. However, co-culture of RBEC with astrocytes did not result in an increase of 
electrical resistance compared to RBEC cultured alone (Figure 6 C). Further experiments are 
planned in which the effect of astrocytes on the permeability of RBEC monolayers will be 
investigated using soluble tracer molecules in this experimental setup. In addition, to further 
dissect the effect of astrocyte loss on the integrity of the BBB additional studies are planned 
using conditional transgenic mouse models where focal loss of astrocytes can be induced 
e.g. by using GFAP Cre-inducible diphtheria toxin receptor (iDTR) mice. 
Beside astrocytes, pericytes are important for the maintenance of endothelial BBB 




brain EC in vitro. Recent in vivo experiments underline the importance of pericytes in the 
establishment and maintenance of the BBB (Armulik et al., 2010; Bell et al., 2010; Daneman 
et al., 2010b). Using transgenic mice with significantly decreased vessel coverage by 
pericytes, an increase in BBB permeability (Armulik et al., 2010; Bell et al., 2010) and age 
dependent reduction of TJ protein expression (Bell et al., 2010) were observed in adult 
animals. Using the pericyte marker platelet-derived growth factor receptor ß (PDGFRß) we 
demonstrated that PDGFRß immunopositive cells line brain vessels in perilesional brain 
tissue (Figure 7 A). This localization was not altered within astrocyte depleted areas 6 h and 
24 h after lesion induction (Figure 7 B, C). This indicates that pericytes are not lost after 
lesion induction and therefore pericyte – EC crosstalk might contribute to the rapid 
restoration of the BBB integrity to soluble molecules after the PMN mediated BBB disruption 
in the absence of astrocytes. 
An important structure which regulates the paracellular diffusion of soluble molecules into 
the brain parenchyma are TJ strands which are located between adjacent brain EC and seal 
the paracellular cleft. Although the TJ structure itself was already described in 1967 using EM 
(Reese and Karnovsky, 1967), the first TJ transmembrane linker protein occludin was only 
discovered in 1993 (Furuse et al., 1993). Besides occludin, another family of transmembrane 
linker proteins has been described: the claudins which are the main structural TJ 
components and consist to date of 27 members (Mineta et al., 2011). Claudin-1, -3, -5 and -
12 have been described to be located at the TJ within the brain (Liebner et al., 2000b; Nitta, 
2003; Wolburg et al., 2003). A disruption of the TJ morphology or loss of TJ proteins from the 
vasculature has been implicated in the breakdown of the BBB, e.g. in MS or glioblastoma 
(Kirk et al., 2003; Liebner et al., 2000a; Plumb et al., 2002; Wolburg et al., 2003). Indeed, we 
observed a transient and selective loss of occludin immunoreactivity from the TJ in NMO-like 
lesions which started 6 h after lesion induction simultaneous with the observation of the 
breakdown of the BBB. At that time point occludin immunoreactivity was detected in 31% of 
the vessels which decreased further to 3.5% after 10 h and 24 h compared to 93% occludin 
positive vessels in control brain tissue. Subsequently occludin expression again increased 
and 6 d after lesion induction no alterations in occludin expression were observed compared 
to uninjected controls (Figure 8). However, although occludin immunoreactivity at the TJ was 
significantly reduced 24 h after lesion induction the integrity of the BBB was already restored 




Although occludin, claudin-3 and claudin-5 were suggested to regulate BBB permeability in 
the CNS, claudin-5 is the only transmembrane molecule that was shown to be crucial for the 
development of a tight BBB. Also, it was shown to be expressed at significantly higher levels 
than claudin-1, -3 or -12 in brain EC (Daneman et al., 2010a; Ohtsuki et al., 2007; Ohtsuki et 
al., 2008). Claudin-5 deficient mice die within 10 h after birth and show a size selective 
permeability to tracer molecules smaller than 800 Da (Nitta, 2003). No BBB specific 
phenotype was detected in occludin or claudin-3 deficient mice (Kooij et al., 2013; Saitou et 
al., 2000), although the latter showed an impaired brain-CSF-barrier. In addition claudins, 
but not occludin were shown to induce de novo TJ formation in mouse fibroblasts in 
transfection studies (Furuse et al., 1998b). Furthermore, overexpression of occludin in 
Madin-Darby canine kidney II (MDCK II) cells, an epithelial cell line, did not result in a 
reduced permeability to uncharged molecules although higher TEER values were measured 
(Van Itallie et al., 2010). However, occludin was suggested to have a regulatory function on 
TJ tightness. In vitro studies showed that occludin transduces cytokine signaling of tumor 
necrosis factor (TNF)-α and interferon (INF)-γ (Van Itallie et al., 2010) and that occludin 
proteolysis or vascular endothelial growth factor (VEGF) signaling could increase 
permeability of cell monolayers (Murakami et al., 2009; Wachtel et al., 1999). The 
experimental data available indicate that the members of the claudin family have key 
functions in the sealing of the paracellular cleft and the induction of the BBB phenotype. 
Therefore, in addition to occludin, we also investigated the expression of claudin-3 and -5 in 
NMO-like lesions. Indeed, no loss of claudin-3 and -5 immunoreactivity from the TJ was 
detected at any time point investigated (Figure 8). This indicates that lack of occludin might 
be compensated for by an intact localization of claudin-3 and -5 at the TJ strands between 
adjacent EC. This is supported by our observation on the ultrastructural level where we did 
not observe overt morphological TJ abnormalities or the separation of adjacent EC 6 h and 
24 h after lesion induction (Figure 9). Furthermore, a rapid increase in mRNA expression of 
occludin and claudin-5 10 h and 24 h after lesion induction might contribute to the re-
establishment of the BBB integrity to soluble tracers (Figure 10). 
4.2 PMN play a crucial role in the breakdown of the BBB in focal NMO like 
lesions 
In neuroinflammatory diseases like NMO or multiple sclerosis (MS) the development of CNS 
lesions is accompanied by the infiltration of immune cells and inflammation mediated 




al., 2002; O'Riordan et al., 1996). To assess whether the immune cell infiltration coincides 
with the disruption of the BBB in NMO-like lesions a time course experiment was performed. 
We detected only few CD3 positive T cells in focal NMO-like lesions starting not until 12 h 
after lesion induction. Furthermore, it was shown in a model of focal NMO-like lesions in 
mice that depletion of T cells does not reduce inflammation, myelin breakdown, or loss of 
AQP4 immunoreactivity (Saadoun et al., 2011) indicating, in line with our data, that T cells 
are not required for the development of NMO-like lesions. Contrary to the scarce infiltration 
of T cells, the infiltration of abundant numbers of PMN, macrophages and monocytes was 
observed. 6 h after lesion induction PMN were the most abundant leukocyte cell type 
observed at the injection site, and their numbers were significantly higher than these of ED1 
positive monocytes/macrophages (Figure 11). Indeed, PMN were shown to be the first cells 
to infiltrate various tissues in other models of infection or tissue damage, e.g. in models of 
peritonitis, colitis (Ajuebor et al., 1999; Cailhier et al., 2005; Yamamoto et al., 2008) or 
ischemia (Barone et al., 1991; Garcia et al., 1994; Matsuo et al., 1994). In our model of NMO-
like lesions the activation of the complement cascade after focal injection of NMO-Ab and 
human complement results in the release of the anaphylatoxin C5a and thus might 
contribute to the rapid recruitment of immune cells into the brain parenchyma. In addition, 
infection or tissue damage result in the release of pathogen- and damage-associated 
molecular pattern molecules (PAMPs and DAMPs), such as lipopolysaccharide (LPS) and 
nuclear or cytoplasmic components released from necrotic cells. PAMPs and DAMPs are 
sensed by resident macrophages and dendritic cells which results in their activation. It was 
shown that there is an early interaction between resident macrophages and PMN in 
response to DAMPs which might represent nuclear and cytoplasmic components released by 
necrotic astrocytes in NMO-like lesions. Activated resident macrophages in turn release pro-
inflammatory cytokines (for example interleukine 8 (IL-8) or TNF-α) and chemokines (e.g. 
chemokine (C-X-C motif) ligand 1 (CXCL1), CXCL2 or CXCL5) which attract PMN from the 
blood into the tissue (Ajuebor et al., 1999; Cailhier et al., 2005; Tian et al., 2007; Yamamoto 
et al., 2008; Yamasaki et al., 2008; Yanai et al., 2009). PMN, in turn, recruit more PMN and 
classical monocytes with the release of diverse granule contents (Chertov et al., 1997; 
Soehnlein et al., 2008) and thereby promote the immune response. 
Indeed, PMN were implied to play a role in the development of human and experimental 
NMO lesions. Infiltration of PMN into the CNS was described in human NMO lesions 
(Lucchinetti et al., 2002) and was present in all NMO biopsies investigated in the present 




et al., 1999). Using ex vivo spinal cord slice cultures it was demonstrated that neutrophils 
exacerbate lesion formation in the presence of a sublytic concentration of NMO-Ab in 
combination with human complement. This exacerbation was associated with the release of 
the PMN protease NE (Zhang et al., 2011). Later, PMN were implicated to participate in Ab-
dependent cell-mediated cytotoxicity (ADCC) against AQP4 expressing astrocytes. Using in 
vitro cell culture and ex vivo spinal cord slice cultures it was shown that eosinophils induced 
cell death of AQP4 positive cells when added to the cultures in combination with 
recombinant NMO-Ab. When eosinophils were added together with a recombinant NMO-Ab 
lacking the ADCC effector function, the loss of AQP4 positive cells was significantly reduced 
(Zhang and Verkman, 2013). The contribution of ADCC mediated astrocyte loss to lesion 
formation was confirmed in vivo in focal NMO-like lesions and after intravenous (i.v.) 
injection of NMO-Ab in myelin basic protein (MBP)-preimmunized rats using the same ADCC 
deficient recombinant NMO-Ab in rats (Wrzos et al., 2014). Furthermore it was suggested 
that astrocyte targeted ADCC is mediated by the low affinity IgG receptor FcγRIII which is 
expressed on PMN and macrophages. Indeed, focal injection of NMO-Ab and human 
complement resulted in significantly smaller lesions in FcγRIII deficient mice compared to wt 
mice. Likewise, systemic treatment with an anti-FcγRII/III Ab resulted in diminished lesion 
development, but also in reduced neutrophil blood counts which might contribute together 
to the reduced pathology that was observed in these mice (Ratelade et al., 2013). In 
addition, we demonstrated that PMN are crucial for the development of NMO-like lesions. 
The development of astrocyte depleted lesions was only observed in control animals, but 
not in animals lacking PMN after treatment with anti-PMN antiserum 6 h after lesion 
induction (Figure 12). This is in line with results published by Saadoun and coworkers. They 
demonstrated that neutropenia induced in mice by injection of rat anti-neutrophil IgG (1A8) 
resulted in a reduction of astrocyte loss and demyelination. In contrast, induction of 
neutrophilia by injection of granulocyte colony stimulating factor significantly exacerbated 
lesion development (Saadoun et al., 2012). 
Thus, our findings that PMN are crucial for development of NMO-like lesions are in line with 
published data in different NMO models. Moreover, we demonstrated that PMN play a 
central role in the regulation of BBB permeability during their infiltration into the brain 
parenchyma 6 h after lesion induction. A strong correlation between the numbers of 
PMN/lesion site and the extent of FITC-albumin extravasation was detected at this time 
point (Figure 11 D). Consequently, depletion of PMN by injection of anti-PMN antiserum 




from the TJ (Figure 12). In addition, we could show that focal injection of a CNS-unspecific 
ctrl-Ab together with human complement also results in the infiltration of, although smaller 
numbers of PMN (Figure 12), coinciding with some leakage of tracer molecules into the 
parenchyma (Figure 4, Figure 5 and Figure 12) and loss of occludin from few TJ (Figure 8). 
This emphasizes the importance of PMN in the induction of BBB permeability upon 
infiltration into the CNS even in the absence of a CNS-specific adaptive immune response. It 
suggests that in our model, a minimal activation of the complement cascade may result in a 
local inflammatory response which in turn leads to the recruitment of PMN into the brain. 
This, however, is substantially amplified by specific Ab-binding after focal injection of NMO-
Ab. 
A loss of BBB integrity induced by PMN transmigration is in line with observations in other 
models of CNS inflammation e.g. in stroke, trauma or experimental autoimmune 
encephalomyelitis (EAE) (Carlson et al., 2008; Neumann et al., 2015; Schnell et al., 1999). 
Using 2-photon imaging it was shown that extravasation of PMN into the CNS is associated 
with a local BBB disruption and infarct formation in an in vivo stroke model (Neumann et al., 
2015). Also trauma-induced lesions in the CNS were associated with leukocyte infiltration 
and increased BBB permeability (Schnell et al., 1999). Furthermore, injection of IL-ß into the 
brain of juvenile rats or chronic expression of IL-1 in the brain resulted in recruitment of 
PMN and a subsequent breakdown of the BBB (Bolton et al., 1998; Ferrari et al., 2004). 
Blockage or deletion of CXCR2, which is important for PMN chemoattraction to the site of 
inflammation, as well as depletion of PMN, resulted in an abrogation of EAE and 
preservation of the BBB integrity. In this study supplementation of wild type (wt) PMN into 
CXCR2 deficient mice was sufficient to restore EAE susceptibility and BBB breakdown 
(Carlson et al., 2008). However, also contrary data is published. It was shown that direct 
injection of activated PMN into the striatum of mice did not affect BBB integrity (Joice et al., 
2009). Additionally, it was demonstrated in vivo and in vitro that transcellular migration of 
PMN by itself does not necessarily result in the induction of increased permeability (von 
Wedel-Parlow et al., 2011; Wolburg et al., 2005). These and other studies also demonstrated 
that in the brain, leukocyte transmigration occurs predominantly by the transcellular 
pathway and that the TJ appeared unaltered in their ultrastructural morphology after 
transmigration (Lossinsky et al., 1989; Raine et al., 1990; von Wedel-Parlow et al., 2011; 
Wolburg et al., 2005). This is in line with our observations in focal NMO-like lesions using 
EM. An ultrastructural TJ morphology similar to that detected in brain vessels of uninjected 




(Figure 9). One possibility to explain the increased permeability despite morphologically 
intact TJ is the published observation that horseradish peroxidase leaks into the brain 
alongside transmigrating inflammatory cells in vivo (Claudio et al., 1990; Lossinsky et al., 
1989) and in vitro (Wong et al., 2007). 
In this study we demonstrated that PMN are the first cells to infiltrate the brain parenchyma, 
that the breakdown of the BBB correlated with PMN extravasation and that depletion of 
PMN from the blood prevented the loss of BBB integrity 6 h after lesion induction. However, 
high numbers of PMN were observed at the injection site 24 h after lesion induction with a 
simultaneous restoration of the BBB integrity to vascular tracers > 690 Da (Figure 5). The 
maximal number of PMN in the lesion was reached between 12 h and 24 h after lesion 
induction with similar numbers of PMN detected around the injection site at both time 
points. This indicates that infiltration of PMN into the brain parenchyma is completed before 
24 h after lesion induction. Once the infiltration of PMN stops, the BBB might be able to 
restore its integrity to soluble molecules. Indeed it was shown in vitro that TNF-α mediated 
PMN transmigration through a brain EC monolayer resulted in induction of permeability to 
horseradish peroxidase at the transmigration site accompanied by decreased TEER values. 
However, at the end of the migration period, the EC layer resumed their continuity and 
integrity to horseradish peroxidase (Wong et al., 2007). In addition, as discussed later in 
more detail, MMP9 released by PMN might play a role in the breakdown of the BBB. We 
demonstrated that 20% of the PMN were immunopositive for MMP9 6 h after lesion 
induction. However, in only 2% of the PMN cellular MMP9 immunoreactivity was detected 
24 h after lesion induction (Figure 16). PMN release their granule contents early after 
activation and infiltration. Therefore, infiltrated PMN might represent a lesser activated 
state at 24 h compared to 6 h after lesion induction. Additionally, it has been shown that 
apoptotic PMN also play a role in the resolution of inflammation. Apoptotic PMN are cleared 
by macrophages. Upon PMN phagocytosis macrophages produce elevated levels of the anti-
inflammatory cytokine IL-10 while the production of the proinflammatory cytokines IL-23 
and IL-12 decreases (Filardy et al., 2010; Stark et al., 2005). Thereby, macrophages assume a 
phenotype that promotes tissue repair. In addition, the resolution of inflammation requires 
the removal of proinflammatory mediators. It has been shown that apoptotic PMN express 
increased levels of CCR5 which can act as a scavenger receptor for the inflammatory 
chemokines CCL3 and CCL5 (Ariel et al., 2006). Additionally, PMN might express decoy 
receptors like the chemokine receptor D6 or IL-1R2 that bind inflammatory cc-chemokines 




However, not only PMN, but also T cells or monocytes were shown to contribute to the 
disruption of the BBB in other inflammatory models such as EAE (Bartholomaus et al., 2009; 
Morrissey et al., 1996; Seeldrayers et al., 1993) or after intracerebral injection of chemokine 
(C-C motif) ligand 2 (Ccl2), an important chemoattracting molecule for 
monocytes/macrophages (Stamatovic et al., 2005). As mentioned above, a role of T cells can 
be excluded in our model. However, a possible role of monocytes in NMO-lesion 
development and in the dysregulation of the BBB cannot be completely ruled out in the 
study presented here. In addition to PMN (201 ± 79 cells/mm²), few (2 ± 2) ED1 (≙CD68) 
positive cells/mm², a marker of monocytes/macrophages, were observed in the brain 
parenchyma 6 h after lesion induction. Although we demonstrated that depletion of PMN 
prevented NMO-like lesion formation, the anti-PMN antiserum used here to deplete PMN 
also resulted in the reduction of peripheral blood cells like monocytes and lymphocytes as 
investigated by flow cytometry (Figure 13). This is in contrast to a previous study which 
showed the treatment of Fischer F344 inbred rats with anti-PMN antiserum to result, beside 
PMN depletion, only in a slight decrease of lymphocytes. The numbers of monocytes in the 
blood were not investigated (Snipes et al., 1995). Therefore, a possible contribution of 
monocytes to lesion development requires further investigation. On the one hand an anti-rat 
neutrophil specific Ab (RP-3) has been described, which we plan to utilize to further specify 
the role of neutrophils in NMO-like lesion development (Sekiya et al., 1989). On the other 
hand we plan to specifically address the role of monocytes in lesion development by using C-
C chemokine receptor type 2 (Ccr2) deficient mice and Ccr2 inhibitors. Ccr2 is expressed on 
inflammatory monocytes and macrophages and is the receptor for Ccl2. It is crucial for 
monocyte chemotaxis and therefore also for the recruitment of monocytes into the inflamed 
tissue (Kurihara et al., 1997; Kuziel et al., 1997). Additionally, Ccr2 positive cells have been 
implied in the disruption of the BBB (Stamatovic et al., 2005). For this purpose NMO-like 
lesions in mice are currently established in our laboratory. 
4.3 PMN attracting molecules and released granule contents modulate NMO-
like lesion development and BBB permeability 
The development of focal NMO-like lesions was shown to be complement-dependent. After 
injection of NMO-Ab and human complement, lesion development is triggered by the 
binding of the NMO-Ab to AQP4 on astrocytes and the subsequent activation of the 
complement cascade which results in astrocyte lysis (Wrzos et al., 2014). Furthermore, 




lesions (Bennett et al., 2009; Lucchinetti et al., 2002) and antibodies defective in 
complement-dependent cytotoxicity (CDC) diminish the formation of NMO-like lesions 
(Ratelade et al., 2013; Tradtrantip et al., 2012; Wrzos et al., 2014). After activation of the 
complement cascade, C5 convertase becomes activated and cleaves the inactive C5 into the 
active component C5b and the anaphylatoxin C5a. Inhibition of this step by using the 
monoclonal antibody eculizumab, directed against C5, inhibits the effector pathway of the 
complement cascade, and significantly reduced attack frequency and improved or stabilized 
the neurological disability measures in NMO patients (Pittock et al., 2013). Further 
downstream, activation of the complement cascade results in the formation of the final 
membrane attack complex resulting in astrocyte lysis. Furthermore, the anaphylatoxin C5a is 
released. Two receptors of C5a are known: the C5a receptor-like 2 (C5L2) and the seven 
transmembrane-containing G protein-coupled receptor C5aR. C5a was shown to be a potent 
peptide mediator of inflammation with C5aR being widely expressed on different cell types. 
In the CNS C5aR is, e.g., expressed by astrocytes, microglia, oligodendrocytes and EC 
(Gasque et al., 1995; Lacy et al., 1995; Laudes et al., 2002; Nataf et al., 2001) and can induce, 
e.g., the expression of adhesion molecules on the endothelial surface (Albrecht et al., 2004). 
Moreover, C5aR is expressed on different immune cells, and C5a acts as an important 
chemoattractant for PMN, macrophages and monocytes (Chenoweth et al., 1982; 
Chenoweth and Hugli, 1978).  
Therefore, we addressed the question whether the development of NMO-like lesions can be 
attenuated by systemic treatment of animals with the small molecule C5aR antagonist PMX-
53 (Finch et al., 1999; Wong et al., 1998), which has been shown to be effective e.g. in the 
treatment of rheumatoid arthritis in rats (Woodruff et al., 2002). Indeed, application of the 
C5a-antagonist 3 h after lesion induction significantly decreased the development of 
astrocyte depletion lesions after 6 h. However, neither the number of infiltrated PMN nor 
the BBB permeability in the lesions was significantly altered after treatment with PMX-53 
(Figure 14). These apparently conflicting data might be explained by the complex functions 
C5aR signaling triggers in PMN. Additionally to the function of C5a as a chemoattractant, 
binding of C5a to C5aR is also implied in the full activation of PMN which is assumed to be a 
two-step process. The first step, also called priming, is mediated by pro-inflammatory 
cytokines such as TNF-α or IL-1 or by the contact with the activated endothelium (Fuortes et 
al., 1993; Lloyds et al., 1995; Nathan et al., 1989; Yagisawa et al., 1995). Full activation can 
be triggered upon exposure to PAMPs, growth factors or chemoattractants like C5a. Binding 




chemotaxis, release of granule enzymes, oxidative burst, phagocytosis and delayed 
apoptosis (Becker et al., 1985; Foreman et al., 1994; Goldstein et al., 1975; Kernen et al., 
1991; Mollnes et al., 2002; Perianayagam et al., 2004; Snyderman and Pike, 1984). 
During lesion initiation the complement mediated lysis of astrocytes may result in the 
development of an inflammatory milieu which results in the activation of the endothelium, 
in which also C5a has been implied. Endothelial cells were also shown to express C5aR and 
activation of C5aR signaling pathways were demonstrated to result in the expression of 
cytokines, chemokines and adhesion molecules on the endothelial surface (Albrecht et al., 
2004). Therefore, the contact of PMN to the activated endothelium at the injection side may 
lead to the priming of PMN and transmigration. This sequence of events is supported by 
observations made by Vincent and coworkers. They demonstrated that NMO-IgG binding to 
astrocytes and subsequent CDC mediated astrocyte lysis resulted in the attraction of PMN 
through an EC monolayer in vitro (Vincent et al., 2008). However, once the BBB is overcome 
PMN of animals treated with C5aR antagonist might fail to become fully activated (Becker et 
al., 1985; Foreman et al., 1994; Goldstein et al., 1975; Kernen et al., 1991; Mollnes et al., 
2002; Perianayagam et al., 2004; Snyderman and Pike, 1984). This might result in reduced 
release of granule contents, reduced phagocytosis and reduced participation in ADCC which 
might result in the reduced loss of astrocyte observed after treatment with the C5aR 
antagonist although the BBB permeability and the number of infiltrated PMN are not 
significantly altered. However, additional in vitro experiments are planned to further 
investigate this hypothesis. The effect of C5a incubation in the absence and presence of 
activated endothelial cells on the activation of PMN will be determined and subsequently 
their ability to lyse astrocytes in an ADCC depended manner together with NMO-Ab will be 
measured. In addition, the effect of C5aR antagonist treatment will be investigated in this 
system. 
To address the question how PMN mediate the breakdown of the BBB, we focused on 
proteases released from PMN granules upon activation, which have been reported to 
contribute to the induction of BBB permeability. During the granulopoiesis in the bone 
marrow PMN granules are formed successively. Four types of granules are known: primary 
(azurophilic), secondary (specific), tertiary (gelatinase) and secretory granules. Granules 
contain different sets of proteases, receptors, adhesion molecules and antibacterial 
proteins. The degree of PMN activation is important for the release of specific granule 




primarily receptors and adhesion molecules (e.g. the ß2-integrin MAC-1, CD14 and 
complement receptor 1). Upon fusion of the secretory vesicle membrane with the cell 
membrane these molecules are expressed on the cell surface and enhance firm adhesion to 
the endothelium and the chemotaxis-directed migration (Borregaard et al., 1990; Detmers et 
al., 1995; Miller et al., 1987; Sengeløv et al., 1994). Subsequently, tertiary and secondary 
granules are released. They contain e.g. the proteases MMP9 and collagenase which 
degrade the basement membrane and extracellular matrix and thereby facilitate PMN egress 
and migration (Dewald et al., 1982; Kjeldsen et al., 1993; Murphy et al., 1980). Primary 
granules are mobilized at the end and thereby release proteins that are thought to 
participate in bactericidal activity and contain, e.g. myeloperoxidase, NE and cathepsin G 
(Cramer et al., 1985; Malemud and Janoff, 1975; Ohlsson and Odsson, 1974). 
MMP9, cathepsin G and NE are PMN proteases that are implied in disruption of the BBB 
(Chen et al., 2009; Hermant et al., 2003; Suzuki et al., 1994). Therefore, we investigated the 
effect of these proteases on the electrical resistance of RBEC in vitro. No alterations in TEER 
values were observed after incubation of RBEC monolayers with either cathepsin G or NE. 
However, treatment of RBEC with MMP9 resulted in a reduction of TEER values by 49.8% 
compared to untreated controls (Figure 15 B). This observation was not due to RBEC death, 
which in turn would result in the disruption of the RBEC monolayer and thereby decrease 
TEER values (Figure 15 C). A possible role of MMP9 released from PMN in the breakdown of 
the BBB has been discussed in the literature. Especially in models of stroke and traumatic 
brain injury, MMP9 may play a crucial role in the disruption of the BBB. Elevated MMP9 
levels are observed in stroke patients and correlate with poor neurologic outcome 
(Castellanos et al., 2003; Horstmann et al., 2003; Montaner et al., 2003). In autopsy tissue, 
MMP9 was mainly detected around vessels and associated with neutrophil infiltration 
(Rosell et al., 2008; Rosell et al., 2006). In experimental models of focal ischemia elevated 
MMP9 levels were demonstrated, which were associated with loss of BBB integrity, 
hemorrhage and neuronal death (Romanic et al., 1998). In MMP9 deficient mice or upon 
pharmacologic MMP inhibition subsequent to induction of focal cerebral ischemia smaller 
lesions and protection of the BBB integrity were described (Asahi et al., 2000; Asahi et al., 
2001; Cui et al., 2012; Gu et al., 2005; Jiang et al., 2001; Koistinaho et al., 2005; Romanic et 
al., 1998; Rosenberg et al., 1998). Comparable findings were observed after traumatic brain 
injury in humans and experimental models (Hadass et al., 2013; Muradashvili et al., 2015; 




In addition, MMP9 has been implied to play a role in MS. Elevated MMP9 levels were 
measured in the CSF of MS patients (Gijbels et al., 1992; Hosokawa et al., 2011; Mandler et 
al., 2001) and in the serum and CNS tissue during EAE (Clements et al., 1997; Kandagaddala 
et al., 2012; Kieseier et al., 1998; Nygårdas and Hinkkanen, 2002). Furthermore, young, 3-4 
week-old MMP9 deficient mice were shown to be less susceptible to EAE compared to age-
matched wt mice. In adult mice, however, no difference in the development and course of 
EAE was observed (Dubois et al., 1999). However, mice deficient in both MMP9 and MMP2 
are resistant to EAE (Agrawal et al., 2006), and also pharmacologic inhibition of MMPs 
ameliorated EAE (Gijbels et al., 1994; Hewson et al., 1995; Niimi et al., 2013). 
Limited data regarding the role of MMP9 in NMO is available. Like in MS the MMP9 CSF 
levels in NMO patients were shown to be elevated. Whether MMP9 levels in the CSF of NMO 
patients differ from those of MS patients is controversial: while one group reported 
significantly higher MMP9 levels in the CSF of NMO patients (Mandler et al., 2001), another 
group did not detect any differences (Hosokawa et al., 2011). However the latter showed 
that serum MMP9 concentrations were significantly higher in NMO than in MS patients and 
correlated with expanded disability status scale scores (EDSS) and BBB disruption, as 
measured by CSF:serum albumin ratios (Hosokawa et al., 2011). Utilizing our model of focal 
NMO-like lesions we could show that 20% of the infiltrating PMN at the injection site were 
immunopositive for MMP9 6 h after lesion induction. At subsequent time points the 
percentage of MMP9 positive PMN decreased. Only 2% of PMN were immunopositive for 
MMP9 24 h after lesion induction, and no MMP9 reactivity was detected on day 3 after 
lesion induction (Figure 16), indicating an early release of MMP9 by PMN. Since treatment of 
RBEC with MMP9 induced a reduction of TEER values in vitro and MMP9 positive PMN were 
only found in early lesions in vivo, MMP9 released by PMN may be an important mediator of 
BBB disruption in NMO-like lesions. However, to investigate the functional effects of MMP9 
on BBB integrity and lesion development in focal NMO-like lesions, further experiments are 
necessary. Studies are planned to assess the effect of pharmacologic inhibition of MMPs by 
using the specific MMP2/MMP9 inhibitor SB-3CT. In addition, we will investigate the 
development of NMO-like lesions and the breakdown of BBB in MMP9 deficient mice. 
However, the mechanism by which MMP9 regulates the BBB permeability is still unknown. 
One proposed mechanism is the cleavage of the TJ molecule occludin by MMP9 (Bojarski, 
2004; Lischper et al., 2010; Liu et al., 2009; Reijerkerk et al., 2006; Yang et al., 2007). Indeed, 




lesion induction. After 6 h, loss of occludin immunoreactivity from about 70% of the vessels 
coincided with infiltration of PMN into the lesions (Figure 8). However, direct incubation of 
RBEC for 2 h with active MMP9 did not result in loss of occludin immunoreactivity from the 
cell-cell contacts although a decrease in TEER values was observed (Figure 15 B, D). To 
further investigate a possible fragmentation of occludin after MMP9 treatment western blot 
analyses will be performed. 
As mentioned before NE did not show a direct effect on TEER values of RBEC in vitro (Figure 
15). However, published data suggests that NE released by PMN might play a role in the 
breakdown of the BBB and in the development of NMO-like lesion in vivo (Saadoun et al., 
2012). To investigate the role of NE in the development of focal NMO-like lesions, the 
competitive NE inhibitor Sivelestat was used. Sivelestat was developed to inhibit human NE, 
but is also effective in other species like rat, rabbit and mouse (Kawabata et al., 1991). 
Indeed, systemic treatment of rats with Sivelestat 3 h after lesion induction resulted in 
significantly smaller astrocyte depleted lesions compared to vehicle treated controls after 
6 h (Figure 17). These results are in line with published data. Zhang and colleagues have 
shown in an ex vivo NMO-model, that incubation of spinal cord slice cultures with 
neutrophils and an insufficient concentration of complement and NMO-Ab resulted in 
exacerbated lesion formation which was significantly reduced after treatment with 
Sivelestat. Conversely, supplementation of NE potentiated lesion development in the 
absence of neutrophils (Zhang et al., 2011). In vivo it was demonstrated in mice that 
intracerebral injection of NMO-Ab and human complement together with Sivelestat and a 
cathepsin G inhibitor reduced lesion size. Similar results were obtained after systemic 
treatment with Sivelestat. In addition, significantly fewer extravasated neutrophils were 
observed within the lesion. (Saadoun et al., 2012). 
Fewer extravasating PMN were also observed in the brain parenchyma in our model after 
treatment with Sivelestat. Surprisingly, this did not result in a decreased permeability of the 
BBB to the vascular tracer FITC-albumin compared to vehicle treated animals (Figure 17). 
Whether NE directly increases the permeability of the BBB is conflicting in the literature. In 
vitro, incubation of EC with activated neutrophils or purified NE was shown to increase 
permeability (Hermant et al., 2003). Furthermore, NE mediated increase of endothelial 
permeability is prevented by Sivelestat (Ikegame et al., 2010; Suzuki et al., 1994). In contrast, 
removal of NE from the secreted supernatant of PMN by immunoabsorption did not result in 




et al., 2000). In vivo, in a rat model of spinal cord injury and in a mouse model of focal 
ischemia, treatment with Sivelestat significantly reduced neurological deficits, neutrophil 
accumulation and BBB disruption (Ikegame et al., 2010; Tonai et al., 2001). However, using 
NE knockout mice it was demonstrated that deficiency of NE exacerbated pathology after 
ventilator-induced lung injury. This was surprising since NE deficient mice showed also lower 
numbers of neutrophils in the alveolar spaces. One possible explanation suggested by the 
authors is the finding that the intercellular adhesion molecule 1 (ICAM-1) is a substrate of NE 
(Champagne et al., 1998; Kaynar et al., 2008). By cleavage of ICAM-1 PMN adhesion to the 
endothelium is terminated and PMN can transmigrate into the tissue. However, in the 
absence of NE the interaction of PMN with the endothelium might be prolonged which leads 
to an increased permeability (Kaynar et al., 2008). This finding gives a possible explanation 
for the discrepancy we observed after treatment with Sivelestat in focal NMO-like lesions 
which resulted in smaller astrocyte depleted lesions and less infiltrating PMN, but no 
difference in BBB permeability (Figure 17). Upon focal injection of NMO-Ab and human 
complement the endothelium becomes activated which may be associated with an 
increased expression of ICAM-1 on the luminal side of the vasculature. This in turn leads to 
ICAM-1 mediated adherence of PMN to the endothelium, which may be prolonged in 
animals treated with Sivelestat, resulting also in reduced numbers of transmigrated cells. 
This explanation is supported by observations made by Saadoun and colleagues. They 
observed that treatment with Sivelestat did not inhibit binding of neutrophils to the 
endothelium, but their extravasation into the brain parenchyma (Saadoun et al., 2012). 
Prolonged contact of activated PMN with endothelial cells was shown to result in cell injury 
(Kaynar et al., 2008) and might therefore induce increases in BBB permeability at the sites of 
PMN adherence resulting in similar tracer extravasation in Sivelestat and vehicle treated 
animals. 
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5 SUMMARY AND CONCLUSIONS 
Neuromyelitis optica (NMO) is a demyelinating autoimmune disease of the central nervous 
system. Astrocytes were shown to be the major target in this disease, and autoantibodies 
against aquaporin4 (AQP4) are detected in about 70% of NMO patients. The binding of 
NMO-antibodies (Ab) to AQP4, a water channel which is highly expressed on astrocytic 
endfeet, results in complement- and cell-mediated depletion of astrocytes in acute lesions. 
The breakdown of the blood-brain barrier (BBB) is an early and prominent event in NMO as 
evidenced by gadolinium enhanced magnetic resonance imaging (MRI), but the structural 
and molecular correlates of the BBB disruption are not yet well understood. We addressed 
this question in a focal NMO model in the rat, which is based on the intracerebral injection 
of a human recombinant NMO-Ab directed against AQP4 together with human complement. 
These lesions mimic key features of early human NMO lesions, including loss of astrocytes 
and oligodendrocytes, demyelination and infiltration of immune cells. 
The development, maintenance and repair of the BBB were shown to be dependent on 
pericytes and astrocytes that closely interact with endothelial cells (EC). Therefore we 
hypothesized that the NMO-Ab mediated depletion of astrocytes in NMO-like lesions might 
contribute to the disruption of the BBB. To investigate this hypothesis, time course 
experiments were performed, which demonstrated that the onset of astrocyte lesion 
development coincided with the breakdown of the BBB 6 h after lesion induction. However, 
the integrity of the BBB to vascular tracers with molecular sizes of > 690 Da was restored 
already after 24 h, at least 2 d before astrocytes repopulated the lesion. Moreover, in a 
transwell co-culture model of the BBB we did not detect alterations in the transendothelial 
resistance of EC monolayers when cultured with or without astrocytes. No loss of pericytes 
from astrocyte depleted lesions was observed. Thus, pericytes might contribute to the 
restoration of the BBB in the absence of astrocytes. 
Furthermore, a detailed analysis of the tight junctions (TJ), which restrict the paracellular 
diffusion of solutes across the BBB, was performed. To investigate if the loss of BBB integrity 
is associated with TJ disruption the expression of occludin, claudin-3 and -5 at the TJ was 
assessed. A transient loss of occludin was detected in NMO-like lesions starting 6 h after 
lesion induction. The expression of claudin-3 and -5 was not altered. Interestingly, the BBB 
integrity to vascular tracer molecules was re-established in the absence of occludin 24 h 
after lesion induction. Moreover, no morphological alterations of the TJ structure were 
observed on the ultrastructural level. Claudin-5, but not occludin or claudin-3, was shown to 
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be crucial for sealing the paracellular cleft which may in part explain these observations. A 
rapid increase of occludin and claudin-5 mRNA expression was found 10 h and 24 h after 
lesion induction which might contribute to the re-establishment of the BBB integrity to 
solutes. 
In models of neuroinflammation it has been demonstrated that infiltrating immune cells 
contribute to the induction of BBB permeability. We found that 6 h after lesion induction 
polymorphonuclear cells (PMN) were the most abundant infiltrating leukocytes. At that time 
point, the number of PMN in the lesions correlated with the extent of FITC-albumin 
extravasation. Consequently, systemic depletion of PMN prevented breakdown of the BBB 
and loss of occludin from the TJ. Interestingly, also astrocyte lesion formation was 
completely abrogated. Since PMN appear to be crucial for astrocyte lesion development we 
hypothesized that the complement component C5a receptor (C5aR), which is important for 
PMN attraction and activation, may be important for lesion development. Indeed, systemic 
treatment of rats with the C5aR antagonist PMX-53 reduced the area of astrocyte loss in 
NMO-like lesions. Additionally, it has been shown that proteases released from PMN 
granules upon activation were involved in the regulation of BBB permeability. We could 
demonstrate that treatment of rat brain EC monolayers with the protease MMP9 decreased 
their electrical resistance in vitro. Also, we detected MMP9 in early infiltrating PMN in focal 
NMO-like lesions after 6 h and 12 h. Furthermore, systemic inhibition of the neutrophil 
elastase using Sivelestat reduced the area of astrocyte loss and the numbers of infiltrating 
PMN in vivo. Ultimately, we showed that infiltrating PMN are a component of the 
inflammatory infiltrate in early human NMO lesions. 
To conclude, this thesis shows a crucial involvement of PMN in the development of NMO-
like lesions. Our data indicate that infiltrating PMN mediate the breakdown of the BBB 6 h 
after lesion induction. This increase in permeability allows complement factors and immune 
cells to gain access to the CNS and to contribute to complement- and cell-mediated 
depletion of astrocytes. These findings together with the detection of PMN in early human 
NMO lesions identify infiltrating PMN and the concomitant breakdown of the BBB as 
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